[
  {
    "sentence": "The corresponding author had full access to all data in the study and had final responsibility to submit for publication.Results\nOf 436 unique records identified (appendix p 6), 59 were identified as relevant (figure 1), and 43 studies were included in our analysis (table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The outcomes in each of these studies were different, but leakage between products was similar in three studies and significantly less among menstrual cups for one study (figure 2).23 In studies that assessed menstrual cups that are still available, the proportion of leakage among the participants who reported use of the menstrual cup was 2–31% for a wide range of definitions, as shown in figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Some factors mentioned in association with leakage by study authors included menorrhagia,48 unusual anatomy of the uterus,53 need for a larger size of menstrual cup,5 and incorrect placement of the menstrual cup, or that it had filled to capacity.39, 53\nFigure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Safety and side-effects of the menstrual cup\n\n\n\n\nn (%) or description\nNotes\nData source\n\n\nHandling and positioning of menstrual cup\nVaginal wound\n\n\nCup not clear (Divacup or softcup)\nEvent April, 2012; vaginal wound due to use of menstrual cup, needing treatment from physician for vaginal bleeding\nComplete medical records were not available for evaluation\nFDA database14\n\n\n\n\nSoftcup (cervical)\nReported April, 2012; long-term customer of softcup product claimed vaginal scarring due to use\nMedical director did not find anything in medical records provided by customer related to vaginal health\nFDA database14\n\n\n\n\nSoftcup (cervical)\nFDA database case report: “…cup wore through the vaginal wall, damaging an artery that required surgical repair”\nEvent could not be confirmed; no medical records were available\nNorth et al (2011)13\n\n\nVaginal pain on removal\n\n\nDivacup (vaginal)\nEvent March, 2017; extreme pain on removal (first use), individual stopped using the cup\nSelf-report; no medical report available\nFDA database14\n\n\nPelvic pain\n\n\nSoftcup (cervical)\nEvent February, 2017; pain in lower pelvis and rectum and nausea about 1 h after insertion, no longer present approximately 30 min after removal\nSelf-report; no medical evaluation available; individual stopped use after trying twice (possibly vascular compression)\nFDA database14\n\n\nVaginal irritation\n\n\nGynaeseal (cervical)\nOne (1%) of 73\nSelf-report by participant\nCattanach et al (1991)39\n\n\n\n\nCervix irritation\n\n\n\nMenses cup (vaginal)\nOne (2%) of 51\nCervical smear was normal\nCheng et al (1995)41\n\n\nAllergy and rash\n\n\nNR, vaginal cup\nAllergy: one (1%) of 150; and rash: two (1%) of 150\n· ·\nKakani et al (2017)48\n\n\n\n\nSoftcup (cervical)\nFDA database: two case reports\nNR\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nEvent 2010: silicone allergy in one individual\nSurgery was needed for vaginal repair; manufacturer noted that silicone allergy is very rare\nFDA database14\n\n\nDifficulty with removal requiring professional assistance\n\n\nGynaeseal (cervical)\nOne (5%) of 22\n· ·\nGleeson et al (1993)46\n\n\n\n\nSoftcup (cervical)\nFDA database: three case reports reported by North 2011; one event in 2018\n· ·\nNorth et al (2011),13 FDA database14\n\n\n\n\nSoftcup (cervical)\nReported complaints to company 2003–08: 42 individuals underwent physician-assisted removal\nOther complaints reported to company included poor fit (n=102), leakage (n=168), messy (n=98)\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nCase report: menstrual cup lodged on cervix, difficult to remove, requiring assistance\nModerate cervical inflammation after retrieval\nDay et al (2012)63\n\n\n\n\nDivacup (vaginal)\nEvent April, 2015: one case report required an emergency room visit for removal\n· ·\nFDA database14\n\n\nReproductive tract observations with use of menstrual cup\nVulva abnormalities\n\n\nSoftcup (cervical)\nBaseline: four (1%) of 393; cycle 1: eight (2%) of 365; cycle 2: six (2%) of 326; cycle 3: five (2%) of 305\nVulva-vaginal inspection at baseline and monthly for 3 months; no p values reported\nNorth et al (2011)13\n\n\nAbnormalities of vaginal wall\n\n\nSoftcup (cervical)\nZero of 44\nVulva-vaginal inspection at baseline and monthly for 3 months\nNorth et al (2011)13\n\n\n\n\nTassette (vaginal)\nZero of 12\nVaginal inspection after 3 months\nPena et al (1962)52\n\n\n\n\nTassette (vaginal)\nZero of 50\nVaginal inspection done; timing of inspections not clear\nKarnaky et al (1962)70\n\n\nAbnormalities of cervix\n\n\nSoftcup (cervical)\nBaseline: 23 (6%) of 390; cycle 1: ten (3%) of 345; cycle 2: six (2%) of 326; cycle 3: four (1%) of 300\nInspection of cervix; no p values reported for differences\nNorth et al (2011)13\n\n\n\n\nSoftcup (cervical)\nAbnormal cervical smear test: baseline: one (<1%) of 406; cycle 1: one (<1%) of 368; cycle 2: two (1%) of 329; cycle 3: zero of 308\nAbnormal cervical smear test results were exclusion criteria at admission, and a reason for discontinuation of the study; no p values reported for differences\nNorth et al (2011)13\n\n\nCondition of vaginal and cervical epithelium\n\n\nSoftcup (cervical)\n44 women examined at baseline, 37 at 2–3 months, and 25 at 5–6 months\n“The Softcup caused no alteration or disruption in vaginal or cervical epithelium, as assessed by colposcopy and cervical cytology”\nNorth et al (2011)13\n\n\nVaginal flora and infections with use of menstrual cup\npH changes of vagina\n\n\nTassette (vaginal)\nZero of 50\nNo abnormalities, vaginal areas where menstrual cup was placed were more acid\nKarnaky et al (1962)70\n\n\n\n\nSoftcup (cervical)\nMean pH at baseline: 4·6 (n=400); cycle 1: 4·6 (n=368); cycle 2: 4·6 (n=329); cycle 3: 4·5 (n=308)\nNo p values reported\nNorth et al (2011)13\n\n\nClue cells (vaginal smear) Lactobaccilus\n\n\nSoftcup (cervical)\nNumber with clue cells: baseline n=6; cycle 1 n=6; cycle 2 n=2; cycle 3 n=4\nSample sizes and p values were not reported\nNorth et al (2011)13\n\n\nLactobaccilus\n\n\nSoftcup (cervical)\n“…before, during, and after use of the cup, vaginal Lactobacillus (normal vaginal flora) was maintained at normal levels.”\nData in figure 3 in publication cannot be extracted; no significant changes according to authors\nNorth et al (2011)13\n\n\nGardnerella vaginalis\n\n\nSoftcup (cervical)\nNo significant changes from baseline-cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nBacterial vaginosis\n\n\nSoftcup (cervical)\nNo significant changes from baseline to cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup 21 (15%) of 144; pads 40 (20%) of 202, and usual practice (control) 32 (21%) of 156; cup vs control p=0·11 and cup vs pads p=0·13; among girls enrolled for ≥9 months: cup 13 (13%) of 101, pads 29 (20%) of 143, usual practice 20 (19%) of 104; cup vs control p=0·07, and cup vs pads p=0·018\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nCandidiasis\n\n\nSoftcup (cervical)\nNumber with candidiasis: baseline n=6; cycle 1 n=6; cycle 2 n=3; cycle 3 n=6\nSample sizes not reported; according to authors, yeast decreased significantly from month 1 to 2\nNorth et al (2011)13\n\n\n\n\nRuby cup (vaginal)\nZero of 18 participants had vaginal candidiasis at follow-up (3–5 months)\nNA\nTellier et al (2012)56\n\n\n\n\nTassette (vaginal)\n\nCandida albicans decreased with the use of the cup\nNR\nKarnaky et al (1962)70\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup 11 (8%) of 143, pads 19 (10%) of 200, usual practice (control) 13 (9%) of 156; cup vs control p=0·87, and cup vs pads p=0·68\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nGroup B Streptococcus\n\n\nSoftcup (cervical)\nNo differences between baseline and cycle 1 to cycle 3\nData in figure 3 in publication cannot be extracted; no significant changes according to authors\nNorth et al (2011)13\n\n\nEnterococcus\n\n\nSoftcup (cervical)\nIncrease in Enterococcus from cycle 2 to cycle 3 (p=0·03)\n“… this increased frequency persisted for 3 months after discontinuing use of the cup, suggesting that factors or behavior other than cup use may have influenced colonization”; data in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nE coli\n\n\nSoftcup (cervical)\nNo significant changes from baseline to cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nEscherichia coli on menstrual cup\n\n\nMooncup (vaginal)\nNine (53%) of 17 if used cup for <6 months; four (22%) of 18 if used for ≥6 months (p=0·12); association between E coli with heavy periods: 61·5% of girls reporting heavy periods had E coli on cups, compared with 22·7% of those stating they did not have heavy periods (p=0·022, no numbers presented)\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nJuma et al (2017)29\n\n\nChlamydia trachomatis\n\n\nMooncup (vaginal)\nStudy end survey: cup three (2%) of 144, pads three (2%) of 201, usual practice (control) seven (5%) of 154; cup vs control p=0·20, and cup vs pads p=0·63\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nTrichomonas vaginalis\n\n\nSoftcup (cervical)\nZero cases at baseline, and cycles 1 to 3\nSample sizes not reported\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup two (1%) of 143, pads five (3%) of 200, usual practice (control) seven (5%) of 154; cup vs control p=0·12, and cup vs pads p=0·36\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\n\n\nRuby cup (vaginal)\nZero of 18 at baseline, and at 3–5 months of follow-up\nNA\nTellier et al (2012)56\n\n\nNeisseria gonorrhoea\n\n\nMooncup (vaginal)\nStudy end survey: cup one (1%) of 144, pads one (1%) of 201, usual practice (control) one (1%) of 154; cup vs control p=0·96, and cup vs pads p=0·81\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\n\n\nRuby cup (vaginal)\nZero of 18 at baseline, and at 3–5 months of follow-up\nNA\nTellier et al (2012)56\n\n\nStaphylococcus aureus\n\n\nSoftcup (cervical)\nNo significant changes in cycles 1–3 compared with baseline\nData in figure 3 of publication cannot be extracted\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nAmong menstrual cup users: four (11%) of 38 in first month of intervention, 13 (9%) of 139 after first month; p=0·83 (median follow-up 4 months, range 2–11 for this substudy); prevalence was 21 (11%) of 197 in sanitary pads group, and 16 (11%) of 153 in usual practice group\nCluster randomised trial in schools; median follow-up 11 months (range 3–15); samples from vaginal swab (self-swabbing)\nJuma et al (2017)29\n\n\n\n\nbe'Cup (vaginal)\nSilicone cup: potentially more S aureus after incubation for 8 h with shaking in a plastic bag with S aureus in one of two cups used, but not when no shaking\nIn-vitro study\nNonfoux et al (2018)73\n\n\n\n\nMe Luna (vaginal)\nThermoplastic isomer cup: no more S aureus after incubation for 8 h with shaking in plastic sac, and not when no shaking\nIn-vitro study\nNonfoux et al (2018)73\n\n\nTSST-1\n\n\nMooncup (vaginal)\n49 schoolgirls with vaginal S aureus had second swab: ten yielded S aureus, two had TSST-1, both in sanitary pad group; the cases were asymptomatic\nCluster randomised trial in schools; median follow-up 11 months (range 3–15); sample from vaginal swab (self-swabbing)\nJuma et al (2017)29\n\n\n\n\nNR\nNo TSST-1 in supernatant of S aureus cultivated for 24 h (incubated aerobically in a still growth environment) in the presence of elastic polymer menstrual cup (n=16 menstrual cups)\nIn-vitro study\nTierno et al (1989)71\n\n\n\n\nTassaway (vaginal)\n\nS aureus MN8 produced no TSST-1 when grown in the presence of Tassaway (elastomeric polymer, n=6), washed or unwashed, no shaking, incubation overnight\nIn-vitro study\nTierno at al (1994)72\n\n\n\n\nbe'Cup (vaginal)\nSilicone cup: potentially more TSST-1 production after incubation for 8 h with shaking in plastic bag with S aureus compared with control, but not when not shaken or with pieces of cup\nIn-vitro study\nNonfoux et al (2018)73\n\n\n\n\nMe Luna (vaginal)\nThermoplastic isomer cup: potentially more TSST-1 production after incubation for 8 h with shaking in plastic bag with S aureus compared with control, but not when not shaken or with pieces of cup\nIn-vitro study\nNonfoux et al (2018)73\n\n\nTSS\n\n\nMooncup (vaginal)\nZero of 192 in trial in Kenya\n“Safety monitoring components comprised routine nurse-based screening, population-based monitoring (school and community) and clinical evaluation of infection with laboratory confirmation”\nJuma et al (2017)29\n\n\n\n\nSoftcup (cervical)\nTwo case reports in the FDA database\nBoth unconfirmed cases of TSS\nNorth et al (2011)13\n\n\n\n\nDivacup (vaginal)\nOne case report: blood cultures and urine culture negative, no culture of the menstrual cup was done\nWoman had history of Hashimoto's thyroiditis and chronic menorrhagia\nMitchell et al (2015)66\n\n\n\n\nMooncup (vaginal)\nEvent February, 2012: TSS 2 days after using of first and new Mooncup resulting in 9 days of inpatient hospital stay; vaginal swab positive for S aureus\n\nHad an IUD, Mooncup was not sent for bacteriological testing\nFDA database14\n\n\n\n\nDivacup (vaginal)\nEvent February, 2015: TSS from Streptococcus resulting in 5 days of i-patient hospital stay; culture of cup isolated group A and B streptococcus\n\nWoman had used Divacup for menstrual period, which started 3 days before illness; menstrual cup was in for 18 h on admission to hospital\nFDA database14\n\n\nUTI\n\n\nRuby cup (vaginal)\nBaseline: four (13%) of 31; at follow-up (after 3–5 months) three (17%) of 18; p=0·65, McNemar test\nOne participant with a UTI at enrolment and follow-up had her cup stolen and used toilet paper in vagina as a tampon\nTellier et al (2012)56\n\n\n\n\nGynaeseal (cervical)\nOne (1%) of 73 had transient dysuria\n“The woman who developed dysuria did not seek treatment and the problem subsided within 24–48 hours”\nCattanach et al (1991)39\n\n\n\n\nSoftcup (cervical)\nUrine analysis done; detailed results not reported\n“Monthly monitoring of gynecological health via urinalysis, pelvic examination with visual evaluation of tissues, vaginal pH, and microscopic wet mount showed no adverse effects of cup use”\nNorth et al (2011)13\n\n\n\n\nSoftcup (cervical)\nEvent August, 2014: UTI confirmed by urine cultures twice after use of softcup\nMedical records were not available for evaluation\nFDA database14\n\n\nInfections overall\n\n\nTassette (vaginal)\n“The amount of bacterial contamination was greatest with the pad, next with the tampon and least with the rubber cup”\nNo data provided; study reported to make cultures from vaginal wall samples and to examine fresh and stained smears for C albicans, Trichomonas vaginalis, Haemophilus vaginalis, and for predominance of Gram-positive or Gram-negative cocci, small rods or long-rod bacilli (Doederlein bacilli)\nKarnaky et al (1962)70\n\n\n\n\nSoftcup (cervical)\nFDA database: one case report\nVaginal infection not further specified; could not be confirmed at follow-up\nNorth et al (2011)13\n\n\n\n\nButterfly cup (vaginal)\n“…none of the women sought treatment for a pelvic infection.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In India22 and Tanzania,43 the uptake of menstrual cups was significantly slower than uptake of pads (appendix p 24).22, 43 In 15 studies with relevant information, 73% (pooled estimate: n=1144, 95% CI 59–84; I2=96%) of participants reported willingness to continue use of the menstrual cup after the study (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The corresponding author had full access to all data in the study and had final responsibility to submit for publication.Results\nOf 436 unique records identified (appendix p 6), 59 were identified as relevant (figure 1), and 43 studies were included in our analysis (table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The outcomes in each of these studies were different, but leakage between products was similar in three studies and significantly less among menstrual cups for one study (figure 2).23 In studies that assessed menstrual cups that are still available, the proportion of leakage among the participants who reported use of the menstrual cup was 2–31% for a wide range of definitions, as shown in figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Some factors mentioned in association with leakage by study authors included menorrhagia,48 unusual anatomy of the uterus,53 need for a larger size of menstrual cup,5 and incorrect placement of the menstrual cup, or that it had filled to capacity.39, 53\nFigure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Safety and side-effects of the menstrual cup\n\n\n\n\nn (%) or description\nNotes\nData source\n\n\nHandling and positioning of menstrual cup\nVaginal wound\n\n\nCup not clear (Divacup or softcup)\nEvent April, 2012; vaginal wound due to use of menstrual cup, needing treatment from physician for vaginal bleeding\nComplete medical records were not available for evaluation\nFDA database14\n\n\n\n\nSoftcup (cervical)\nReported April, 2012; long-term customer of softcup product claimed vaginal scarring due to use\nMedical director did not find anything in medical records provided by customer related to vaginal health\nFDA database14\n\n\n\n\nSoftcup (cervical)\nFDA database case report: “…cup wore through the vaginal wall, damaging an artery that required surgical repair”\nEvent could not be confirmed; no medical records were available\nNorth et al (2011)13\n\n\nVaginal pain on removal\n\n\nDivacup (vaginal)\nEvent March, 2017; extreme pain on removal (first use), individual stopped using the cup\nSelf-report; no medical report available\nFDA database14\n\n\nPelvic pain\n\n\nSoftcup (cervical)\nEvent February, 2017; pain in lower pelvis and rectum and nausea about 1 h after insertion, no longer present approximately 30 min after removal\nSelf-report; no medical evaluation available; individual stopped use after trying twice (possibly vascular compression)\nFDA database14\n\n\nVaginal irritation\n\n\nGynaeseal (cervical)\nOne (1%) of 73\nSelf-report by participant\nCattanach et al (1991)39\n\n\n\n\nCervix irritation\n\n\n\nMenses cup (vaginal)\nOne (2%) of 51\nCervical smear was normal\nCheng et al (1995)41\n\n\nAllergy and rash\n\n\nNR, vaginal cup\nAllergy: one (1%) of 150; and rash: two (1%) of 150\n· ·\nKakani et al (2017)48\n\n\n\n\nSoftcup (cervical)\nFDA database: two case reports\nNR\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nEvent 2010: silicone allergy in one individual\nSurgery was needed for vaginal repair; manufacturer noted that silicone allergy is very rare\nFDA database14\n\n\nDifficulty with removal requiring professional assistance\n\n\nGynaeseal (cervical)\nOne (5%) of 22\n· ·\nGleeson et al (1993)46\n\n\n\n\nSoftcup (cervical)\nFDA database: three case reports reported by North 2011; one event in 2018\n· ·\nNorth et al (2011),13 FDA database14\n\n\n\n\nSoftcup (cervical)\nReported complaints to company 2003–08: 42 individuals underwent physician-assisted removal\nOther complaints reported to company included poor fit (n=102), leakage (n=168), messy (n=98)\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nCase report: menstrual cup lodged on cervix, difficult to remove, requiring assistance\nModerate cervical inflammation after retrieval\nDay et al (2012)63\n\n\n\n\nDivacup (vaginal)\nEvent April, 2015: one case report required an emergency room visit for removal\n· ·\nFDA database14\n\n\nReproductive tract observations with use of menstrual cup\nVulva abnormalities\n\n\nSoftcup (cervical)\nBaseline: four (1%) of 393; cycle 1: eight (2%) of 365; cycle 2: six (2%) of 326; cycle 3: five (2%) of 305\nVulva-vaginal inspection at baseline and monthly for 3 months; no p values reported\nNorth et al (2011)13\n\n\nAbnormalities of vaginal wall\n\n\nSoftcup (cervical)\nZero of 44\nVulva-vaginal inspection at baseline and monthly for 3 months\nNorth et al (2011)13\n\n\n\n\nTassette (vaginal)\nZero of 12\nVaginal inspection after 3 months\nPena et al (1962)52\n\n\n\n\nTassette (vaginal)\nZero of 50\nVaginal inspection done; timing of inspections not clear\nKarnaky et al (1962)70\n\n\nAbnormalities of cervix\n\n\nSoftcup (cervical)\nBaseline: 23 (6%) of 390; cycle 1: ten (3%) of 345; cycle 2: six (2%) of 326; cycle 3: four (1%) of 300\nInspection of cervix; no p values reported for differences\nNorth et al (2011)13\n\n\n\n\nSoftcup (cervical)\nAbnormal cervical smear test: baseline: one (<1%) of 406; cycle 1: one (<1%) of 368; cycle 2: two (1%) of 329; cycle 3: zero of 308\nAbnormal cervical smear test results were exclusion criteria at admission, and a reason for discontinuation of the study; no p values reported for differences\nNorth et al (2011)13\n\n\nCondition of vaginal and cervical epithelium\n\n\nSoftcup (cervical)\n44 women examined at baseline, 37 at 2–3 months, and 25 at 5–6 months\n“The Softcup caused no alteration or disruption in vaginal or cervical epithelium, as assessed by colposcopy and cervical cytology”\nNorth et al (2011)13\n\n\nVaginal flora and infections with use of menstrual cup\npH changes of vagina\n\n\nTassette (vaginal)\nZero of 50\nNo abnormalities, vaginal areas where menstrual cup was placed were more acid\nKarnaky et al (1962)70\n\n\n\n\nSoftcup (cervical)\nMean pH at baseline: 4·6 (n=400); cycle 1: 4·6 (n=368); cycle 2: 4·6 (n=329); cycle 3: 4·5 (n=308)\nNo p values reported\nNorth et al (2011)13\n\n\nClue cells (vaginal smear) Lactobaccilus\n\n\nSoftcup (cervical)\nNumber with clue cells: baseline n=6; cycle 1 n=6; cycle 2 n=2; cycle 3 n=4\nSample sizes and p values were not reported\nNorth et al (2011)13\n\n\nLactobaccilus\n\n\nSoftcup (cervical)\n“…before, during, and after use of the cup, vaginal Lactobacillus (normal vaginal flora) was maintained at normal levels.”\nData in figure 3 in publication cannot be extracted; no significant changes according to authors\nNorth et al (2011)13\n\n\nGardnerella vaginalis\n\n\nSoftcup (cervical)\nNo significant changes from baseline-cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nBacterial vaginosis\n\n\nSoftcup (cervical)\nNo significant changes from baseline to cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup 21 (15%) of 144; pads 40 (20%) of 202, and usual practice (control) 32 (21%) of 156; cup vs control p=0·11 and cup vs pads p=0·13; among girls enrolled for ≥9 months: cup 13 (13%) of 101, pads 29 (20%) of 143, usual practice 20 (19%) of 104; cup vs control p=0·07, and cup vs pads p=0·018\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nCandidiasis\n\n\nSoftcup (cervical)\nNumber with candidiasis: baseline n=6; cycle 1 n=6; cycle 2 n=3; cycle 3 n=6\nSample sizes not reported; according to authors, yeast decreased significantly from month 1 to 2\nNorth et al (2011)13\n\n\n\n\nRuby cup (vaginal)\nZero of 18 participants had vaginal candidiasis at follow-up (3–5 months)\nNA\nTellier et al (2012)56\n\n\n\n\nTassette (vaginal)\n\nCandida albicans decreased with the use of the cup\nNR\nKarnaky et al (1962)70\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup 11 (8%) of 143, pads 19 (10%) of 200, usual practice (control) 13 (9%) of 156; cup vs control p=0·87, and cup vs pads p=0·68\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nGroup B Streptococcus\n\n\nSoftcup (cervical)\nNo differences between baseline and cycle 1 to cycle 3\nData in figure 3 in publication cannot be extracted; no significant changes according to authors\nNorth et al (2011)13\n\n\nEnterococcus\n\n\nSoftcup (cervical)\nIncrease in Enterococcus from cycle 2 to cycle 3 (p=0·03)\n“… this increased frequency persisted for 3 months after discontinuing use of the cup, suggesting that factors or behavior other than cup use may have influenced colonization”; data in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nE coli\n\n\nSoftcup (cervical)\nNo significant changes from baseline to cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nEscherichia coli on menstrual cup\n\n\nMooncup (vaginal)\nNine (53%) of 17 if used cup for <6 months; four (22%) of 18 if used for ≥6 months (p=0·12); association between E coli with heavy periods: 61·5% of girls reporting heavy periods had E coli on cups, compared with 22·7% of those stating they did not have heavy periods (p=0·022, no numbers presented)\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nJuma et al (2017)29\n\n\nChlamydia trachomatis\n\n\nMooncup (vaginal)\nStudy end survey: cup three (2%) of 144, pads three (2%) of 201, usual practice (control) seven (5%) of 154; cup vs control p=0·20, and cup vs pads p=0·63\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nTrichomonas vaginalis\n\n\nSoftcup (cervical)\nZero cases at baseline, and cycles 1 to 3\nSample sizes not reported\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup two (1%) of 143, pads five (3%) of 200, usual practice (control) seven (5%) of 154; cup vs control p=0·12, and cup vs pads p=0·36\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\n\n\nRuby cup (vaginal)\nZero of 18 at baseline, and at 3–5 months of follow-up\nNA\nTellier et al (2012)56\n\n\nNeisseria gonorrhoea\n\n\nMooncup (vaginal)\nStudy end survey: cup one (1%) of 144, pads one (1%) of 201, usual practice (control) one (1%) of 154; cup vs control p=0·96, and cup vs pads p=0·81\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\n\n\nRuby cup (vaginal)\nZero of 18 at baseline, and at 3–5 months of follow-up\nNA\nTellier et al (2012)56\n\n\nStaphylococcus aureus\n\n\nSoftcup (cervical)\nNo significant changes in cycles 1–3 compared with baseline\nData in figure 3 of publication cannot be extracted\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nAmong menstrual cup users: four (11%) of 38 in first month of intervention, 13 (9%) of 139 after first month; p=0·83 (median follow-up 4 months, range 2–11 for this substudy); prevalence was 21 (11%) of 197 in sanitary pads group, and 16 (11%) of 153 in usual practice group\nCluster randomised trial in schools; median follow-up 11 months (range 3–15); samples from vaginal swab (self-swabbing)\nJuma et al (2017)29\n\n\n\n\nbe'Cup (vaginal)\nSilicone cup: potentially more S aureus after incubation for 8 h with shaking in a plastic bag with S aureus in one of two cups used, but not when no shaking\nIn-vitro study\nNonfoux et al (2018)73\n\n\n\n\nMe Luna (vaginal)\nThermoplastic isomer cup: no more S aureus after incubation for 8 h with shaking in plastic sac, and not when no shaking\nIn-vitro study\nNonfoux et al (2018)73\n\n\nTSST-1\n\n\nMooncup (vaginal)\n49 schoolgirls with vaginal S aureus had second swab: ten yielded S aureus, two had TSST-1, both in sanitary pad group; the cases were asymptomatic\nCluster randomised trial in schools; median follow-up 11 months (range 3–15); sample from vaginal swab (self-swabbing)\nJuma et al (2017)29\n\n\n\n\nNR\nNo TSST-1 in supernatant of S aureus cultivated for 24 h (incubated aerobically in a still growth environment) in the presence of elastic polymer menstrual cup (n=16 menstrual cups)\nIn-vitro study\nTierno et al (1989)71\n\n\n\n\nTassaway (vaginal)\n\nS aureus MN8 produced no TSST-1 when grown in the presence of Tassaway (elastomeric polymer, n=6), washed or unwashed, no shaking, incubation overnight\nIn-vitro study\nTierno at al (1994)72\n\n\n\n\nbe'Cup (vaginal)\nSilicone cup: potentially more TSST-1 production after incubation for 8 h with shaking in plastic bag with S aureus compared with control, but not when not shaken or with pieces of cup\nIn-vitro study\nNonfoux et al (2018)73\n\n\n\n\nMe Luna (vaginal)\nThermoplastic isomer cup: potentially more TSST-1 production after incubation for 8 h with shaking in plastic bag with S aureus compared with control, but not when not shaken or with pieces of cup\nIn-vitro study\nNonfoux et al (2018)73\n\n\nTSS\n\n\nMooncup (vaginal)\nZero of 192 in trial in Kenya\n“Safety monitoring components comprised routine nurse-based screening, population-based monitoring (school and community) and clinical evaluation of infection with laboratory confirmation”\nJuma et al (2017)29\n\n\n\n\nSoftcup (cervical)\nTwo case reports in the FDA database\nBoth unconfirmed cases of TSS\nNorth et al (2011)13\n\n\n\n\nDivacup (vaginal)\nOne case report: blood cultures and urine culture negative, no culture of the menstrual cup was done\nWoman had history of Hashimoto's thyroiditis and chronic menorrhagia\nMitchell et al (2015)66\n\n\n\n\nMooncup (vaginal)\nEvent February, 2012: TSS 2 days after using of first and new Mooncup resulting in 9 days of inpatient hospital stay; vaginal swab positive for S aureus\n\nHad an IUD, Mooncup was not sent for bacteriological testing\nFDA database14\n\n\n\n\nDivacup (vaginal)\nEvent February, 2015: TSS from Streptococcus resulting in 5 days of i-patient hospital stay; culture of cup isolated group A and B streptococcus\n\nWoman had used Divacup for menstrual period, which started 3 days before illness; menstrual cup was in for 18 h on admission to hospital\nFDA database14\n\n\nUTI\n\n\nRuby cup (vaginal)\nBaseline: four (13%) of 31; at follow-up (after 3–5 months) three (17%) of 18; p=0·65, McNemar test\nOne participant with a UTI at enrolment and follow-up had her cup stolen and used toilet paper in vagina as a tampon\nTellier et al (2012)56\n\n\n\n\nGynaeseal (cervical)\nOne (1%) of 73 had transient dysuria\n“The woman who developed dysuria did not seek treatment and the problem subsided within 24–48 hours”\nCattanach et al (1991)39\n\n\n\n\nSoftcup (cervical)\nUrine analysis done; detailed results not reported\n“Monthly monitoring of gynecological health via urinalysis, pelvic examination with visual evaluation of tissues, vaginal pH, and microscopic wet mount showed no adverse effects of cup use”\nNorth et al (2011)13\n\n\n\n\nSoftcup (cervical)\nEvent August, 2014: UTI confirmed by urine cultures twice after use of softcup\nMedical records were not available for evaluation\nFDA database14\n\n\nInfections overall\n\n\nTassette (vaginal)\n“The amount of bacterial contamination was greatest with the pad, next with the tampon and least with the rubber cup”\nNo data provided; study reported to make cultures from vaginal wall samples and to examine fresh and stained smears for C albicans, Trichomonas vaginalis, Haemophilus vaginalis, and for predominance of Gram-positive or Gram-negative cocci, small rods or long-rod bacilli (Doederlein bacilli)\nKarnaky et al (1962)70\n\n\n\n\nSoftcup (cervical)\nFDA database: one case report\nVaginal infection not further specified; could not be confirmed at follow-up\nNorth et al (2011)13\n\n\n\n\nButterfly cup (vaginal)\n“…none of the women sought treatment for a pelvic infection.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In India22 and Tanzania,43 the uptake of menstrual cups was significantly slower than uptake of pads (appendix p 24).22, 43 In 15 studies with relevant information, 73% (pooled estimate: n=1144, 95% CI 59–84; I2=96%) of participants reported willingness to continue use of the menstrual cup after the study (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The corresponding author had full access to all data in the study and had final responsibility to submit for publication.Results\nOf 436 unique records identified (appendix p 6), 59 were identified as relevant (figure 1), and 43 studies were included in our analysis (table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The outcomes in each of these studies were different, but leakage between products was similar in three studies and significantly less among menstrual cups for one study (figure 2).23 In studies that assessed menstrual cups that are still available, the proportion of leakage among the participants who reported use of the menstrual cup was 2–31% for a wide range of definitions, as shown in figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Some factors mentioned in association with leakage by study authors included menorrhagia,48 unusual anatomy of the uterus,53 need for a larger size of menstrual cup,5 and incorrect placement of the menstrual cup, or that it had filled to capacity.39, 53\nFigure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Safety and side-effects of the menstrual cup\n\n\n\n\nn (%) or description\nNotes\nData source\n\n\nHandling and positioning of menstrual cup\nVaginal wound\n\n\nCup not clear (Divacup or softcup)\nEvent April, 2012; vaginal wound due to use of menstrual cup, needing treatment from physician for vaginal bleeding\nComplete medical records were not available for evaluation\nFDA database14\n\n\n\n\nSoftcup (cervical)\nReported April, 2012; long-term customer of softcup product claimed vaginal scarring due to use\nMedical director did not find anything in medical records provided by customer related to vaginal health\nFDA database14\n\n\n\n\nSoftcup (cervical)\nFDA database case report: “…cup wore through the vaginal wall, damaging an artery that required surgical repair”\nEvent could not be confirmed; no medical records were available\nNorth et al (2011)13\n\n\nVaginal pain on removal\n\n\nDivacup (vaginal)\nEvent March, 2017; extreme pain on removal (first use), individual stopped using the cup\nSelf-report; no medical report available\nFDA database14\n\n\nPelvic pain\n\n\nSoftcup (cervical)\nEvent February, 2017; pain in lower pelvis and rectum and nausea about 1 h after insertion, no longer present approximately 30 min after removal\nSelf-report; no medical evaluation available; individual stopped use after trying twice (possibly vascular compression)\nFDA database14\n\n\nVaginal irritation\n\n\nGynaeseal (cervical)\nOne (1%) of 73\nSelf-report by participant\nCattanach et al (1991)39\n\n\n\n\nCervix irritation\n\n\n\nMenses cup (vaginal)\nOne (2%) of 51\nCervical smear was normal\nCheng et al (1995)41\n\n\nAllergy and rash\n\n\nNR, vaginal cup\nAllergy: one (1%) of 150; and rash: two (1%) of 150\n· ·\nKakani et al (2017)48\n\n\n\n\nSoftcup (cervical)\nFDA database: two case reports\nNR\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nEvent 2010: silicone allergy in one individual\nSurgery was needed for vaginal repair; manufacturer noted that silicone allergy is very rare\nFDA database14\n\n\nDifficulty with removal requiring professional assistance\n\n\nGynaeseal (cervical)\nOne (5%) of 22\n· ·\nGleeson et al (1993)46\n\n\n\n\nSoftcup (cervical)\nFDA database: three case reports reported by North 2011; one event in 2018\n· ·\nNorth et al (2011),13 FDA database14\n\n\n\n\nSoftcup (cervical)\nReported complaints to company 2003–08: 42 individuals underwent physician-assisted removal\nOther complaints reported to company included poor fit (n=102), leakage (n=168), messy (n=98)\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nCase report: menstrual cup lodged on cervix, difficult to remove, requiring assistance\nModerate cervical inflammation after retrieval\nDay et al (2012)63\n\n\n\n\nDivacup (vaginal)\nEvent April, 2015: one case report required an emergency room visit for removal\n· ·\nFDA database14\n\n\nReproductive tract observations with use of menstrual cup\nVulva abnormalities\n\n\nSoftcup (cervical)\nBaseline: four (1%) of 393; cycle 1: eight (2%) of 365; cycle 2: six (2%) of 326; cycle 3: five (2%) of 305\nVulva-vaginal inspection at baseline and monthly for 3 months; no p values reported\nNorth et al (2011)13\n\n\nAbnormalities of vaginal wall\n\n\nSoftcup (cervical)\nZero of 44\nVulva-vaginal inspection at baseline and monthly for 3 months\nNorth et al (2011)13\n\n\n\n\nTassette (vaginal)\nZero of 12\nVaginal inspection after 3 months\nPena et al (1962)52\n\n\n\n\nTassette (vaginal)\nZero of 50\nVaginal inspection done; timing of inspections not clear\nKarnaky et al (1962)70\n\n\nAbnormalities of cervix\n\n\nSoftcup (cervical)\nBaseline: 23 (6%) of 390; cycle 1: ten (3%) of 345; cycle 2: six (2%) of 326; cycle 3: four (1%) of 300\nInspection of cervix; no p values reported for differences\nNorth et al (2011)13\n\n\n\n\nSoftcup (cervical)\nAbnormal cervical smear test: baseline: one (<1%) of 406; cycle 1: one (<1%) of 368; cycle 2: two (1%) of 329; cycle 3: zero of 308\nAbnormal cervical smear test results were exclusion criteria at admission, and a reason for discontinuation of the study; no p values reported for differences\nNorth et al (2011)13\n\n\nCondition of vaginal and cervical epithelium\n\n\nSoftcup (cervical)\n44 women examined at baseline, 37 at 2–3 months, and 25 at 5–6 months\n“The Softcup caused no alteration or disruption in vaginal or cervical epithelium, as assessed by colposcopy and cervical cytology”\nNorth et al (2011)13\n\n\nVaginal flora and infections with use of menstrual cup\npH changes of vagina\n\n\nTassette (vaginal)\nZero of 50\nNo abnormalities, vaginal areas where menstrual cup was placed were more acid\nKarnaky et al (1962)70\n\n\n\n\nSoftcup (cervical)\nMean pH at baseline: 4·6 (n=400); cycle 1: 4·6 (n=368); cycle 2: 4·6 (n=329); cycle 3: 4·5 (n=308)\nNo p values reported\nNorth et al (2011)13\n\n\nClue cells (vaginal smear) Lactobaccilus\n\n\nSoftcup (cervical)\nNumber with clue cells: baseline n=6; cycle 1 n=6; cycle 2 n=2; cycle 3 n=4\nSample sizes and p values were not reported\nNorth et al (2011)13\n\n\nLactobaccilus\n\n\nSoftcup (cervical)\n“…before, during, and after use of the cup, vaginal Lactobacillus (normal vaginal flora) was maintained at normal levels.”\nData in figure 3 in publication cannot be extracted; no significant changes according to authors\nNorth et al (2011)13\n\n\nGardnerella vaginalis\n\n\nSoftcup (cervical)\nNo significant changes from baseline-cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nBacterial vaginosis\n\n\nSoftcup (cervical)\nNo significant changes from baseline to cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup 21 (15%) of 144; pads 40 (20%) of 202, and usual practice (control) 32 (21%) of 156; cup vs control p=0·11 and cup vs pads p=0·13; among girls enrolled for ≥9 months: cup 13 (13%) of 101, pads 29 (20%) of 143, usual practice 20 (19%) of 104; cup vs control p=0·07, and cup vs pads p=0·018\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nCandidiasis\n\n\nSoftcup (cervical)\nNumber with candidiasis: baseline n=6; cycle 1 n=6; cycle 2 n=3; cycle 3 n=6\nSample sizes not reported; according to authors, yeast decreased significantly from month 1 to 2\nNorth et al (2011)13\n\n\n\n\nRuby cup (vaginal)\nZero of 18 participants had vaginal candidiasis at follow-up (3–5 months)\nNA\nTellier et al (2012)56\n\n\n\n\nTassette (vaginal)\n\nCandida albicans decreased with the use of the cup\nNR\nKarnaky et al (1962)70\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup 11 (8%) of 143, pads 19 (10%) of 200, usual practice (control) 13 (9%) of 156; cup vs control p=0·87, and cup vs pads p=0·68\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nGroup B Streptococcus\n\n\nSoftcup (cervical)\nNo differences between baseline and cycle 1 to cycle 3\nData in figure 3 in publication cannot be extracted; no significant changes according to authors\nNorth et al (2011)13\n\n\nEnterococcus\n\n\nSoftcup (cervical)\nIncrease in Enterococcus from cycle 2 to cycle 3 (p=0·03)\n“… this increased frequency persisted for 3 months after discontinuing use of the cup, suggesting that factors or behavior other than cup use may have influenced colonization”; data in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nE coli\n\n\nSoftcup (cervical)\nNo significant changes from baseline to cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nEscherichia coli on menstrual cup\n\n\nMooncup (vaginal)\nNine (53%) of 17 if used cup for <6 months; four (22%) of 18 if used for ≥6 months (p=0·12); association between E coli with heavy periods: 61·5% of girls reporting heavy periods had E coli on cups, compared with 22·7% of those stating they did not have heavy periods (p=0·022, no numbers presented)\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nJuma et al (2017)29\n\n\nChlamydia trachomatis\n\n\nMooncup (vaginal)\nStudy end survey: cup three (2%) of 144, pads three (2%) of 201, usual practice (control) seven (5%) of 154; cup vs control p=0·20, and cup vs pads p=0·63\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nTrichomonas vaginalis\n\n\nSoftcup (cervical)\nZero cases at baseline, and cycles 1 to 3\nSample sizes not reported\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup two (1%) of 143, pads five (3%) of 200, usual practice (control) seven (5%) of 154; cup vs control p=0·12, and cup vs pads p=0·36\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\n\n\nRuby cup (vaginal)\nZero of 18 at baseline, and at 3–5 months of follow-up\nNA\nTellier et al (2012)56\n\n\nNeisseria gonorrhoea\n\n\nMooncup (vaginal)\nStudy end survey: cup one (1%) of 144, pads one (1%) of 201, usual practice (control) one (1%) of 154; cup vs control p=0·96, and cup vs pads p=0·81\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\n\n\nRuby cup (vaginal)\nZero of 18 at baseline, and at 3–5 months of follow-up\nNA\nTellier et al (2012)56\n\n\nStaphylococcus aureus\n\n\nSoftcup (cervical)\nNo significant changes in cycles 1–3 compared with baseline\nData in figure 3 of publication cannot be extracted\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nAmong menstrual cup users: four (11%) of 38 in first month of intervention, 13 (9%) of 139 after first month; p=0·83 (median follow-up 4 months, range 2–11 for this substudy); prevalence was 21 (11%) of 197 in sanitary pads group, and 16 (11%) of 153 in usual practice group\nCluster randomised trial in schools; median follow-up 11 months (range 3–15); samples from vaginal swab (self-swabbing)\nJuma et al (2017)29\n\n\n\n\nbe'Cup (vaginal)\nSilicone cup: potentially more S aureus after incubation for 8 h with shaking in a plastic bag with S aureus in one of two cups used, but not when no shaking\nIn-vitro study\nNonfoux et al (2018)73\n\n\n\n\nMe Luna (vaginal)\nThermoplastic isomer cup: no more S aureus after incubation for 8 h with shaking in plastic sac, and not when no shaking\nIn-vitro study\nNonfoux et al (2018)73\n\n\nTSST-1\n\n\nMooncup (vaginal)\n49 schoolgirls with vaginal S aureus had second swab: ten yielded S aureus, two had TSST-1, both in sanitary pad group; the cases were asymptomatic\nCluster randomised trial in schools; median follow-up 11 months (range 3–15); sample from vaginal swab (self-swabbing)\nJuma et al (2017)29\n\n\n\n\nNR\nNo TSST-1 in supernatant of S aureus cultivated for 24 h (incubated aerobically in a still growth environment) in the presence of elastic polymer menstrual cup (n=16 menstrual cups)\nIn-vitro study\nTierno et al (1989)71\n\n\n\n\nTassaway (vaginal)\n\nS aureus MN8 produced no TSST-1 when grown in the presence of Tassaway (elastomeric polymer, n=6), washed or unwashed, no shaking, incubation overnight\nIn-vitro study\nTierno at al (1994)72\n\n\n\n\nbe'Cup (vaginal)\nSilicone cup: potentially more TSST-1 production after incubation for 8 h with shaking in plastic bag with S aureus compared with control, but not when not shaken or with pieces of cup\nIn-vitro study\nNonfoux et al (2018)73\n\n\n\n\nMe Luna (vaginal)\nThermoplastic isomer cup: potentially more TSST-1 production after incubation for 8 h with shaking in plastic bag with S aureus compared with control, but not when not shaken or with pieces of cup\nIn-vitro study\nNonfoux et al (2018)73\n\n\nTSS\n\n\nMooncup (vaginal)\nZero of 192 in trial in Kenya\n“Safety monitoring components comprised routine nurse-based screening, population-based monitoring (school and community) and clinical evaluation of infection with laboratory confirmation”\nJuma et al (2017)29\n\n\n\n\nSoftcup (cervical)\nTwo case reports in the FDA database\nBoth unconfirmed cases of TSS\nNorth et al (2011)13\n\n\n\n\nDivacup (vaginal)\nOne case report: blood cultures and urine culture negative, no culture of the menstrual cup was done\nWoman had history of Hashimoto's thyroiditis and chronic menorrhagia\nMitchell et al (2015)66\n\n\n\n\nMooncup (vaginal)\nEvent February, 2012: TSS 2 days after using of first and new Mooncup resulting in 9 days of inpatient hospital stay; vaginal swab positive for S aureus\n\nHad an IUD, Mooncup was not sent for bacteriological testing\nFDA database14\n\n\n\n\nDivacup (vaginal)\nEvent February, 2015: TSS from Streptococcus resulting in 5 days of i-patient hospital stay; culture of cup isolated group A and B streptococcus\n\nWoman had used Divacup for menstrual period, which started 3 days before illness; menstrual cup was in for 18 h on admission to hospital\nFDA database14\n\n\nUTI\n\n\nRuby cup (vaginal)\nBaseline: four (13%) of 31; at follow-up (after 3–5 months) three (17%) of 18; p=0·65, McNemar test\nOne participant with a UTI at enrolment and follow-up had her cup stolen and used toilet paper in vagina as a tampon\nTellier et al (2012)56\n\n\n\n\nGynaeseal (cervical)\nOne (1%) of 73 had transient dysuria\n“The woman who developed dysuria did not seek treatment and the problem subsided within 24–48 hours”\nCattanach et al (1991)39\n\n\n\n\nSoftcup (cervical)\nUrine analysis done; detailed results not reported\n“Monthly monitoring of gynecological health via urinalysis, pelvic examination with visual evaluation of tissues, vaginal pH, and microscopic wet mount showed no adverse effects of cup use”\nNorth et al (2011)13\n\n\n\n\nSoftcup (cervical)\nEvent August, 2014: UTI confirmed by urine cultures twice after use of softcup\nMedical records were not available for evaluation\nFDA database14\n\n\nInfections overall\n\n\nTassette (vaginal)\n“The amount of bacterial contamination was greatest with the pad, next with the tampon and least with the rubber cup”\nNo data provided; study reported to make cultures from vaginal wall samples and to examine fresh and stained smears for C albicans, Trichomonas vaginalis, Haemophilus vaginalis, and for predominance of Gram-positive or Gram-negative cocci, small rods or long-rod bacilli (Doederlein bacilli)\nKarnaky et al (1962)70\n\n\n\n\nSoftcup (cervical)\nFDA database: one case report\nVaginal infection not further specified; could not be confirmed at follow-up\nNorth et al (2011)13\n\n\n\n\nButterfly cup (vaginal)\n“…none of the women sought treatment for a pelvic infection.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In India22 and Tanzania,43 the uptake of menstrual cups was significantly slower than uptake of pads (appendix p 24).22, 43 In 15 studies with relevant information, 73% (pooled estimate: n=1144, 95% CI 59–84; I2=96%) of participants reported willingness to continue use of the menstrual cup after the study (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The corresponding author had full access to all data in the study and had final responsibility to submit for publication.Results\nOf 436 unique records identified (appendix p 6), 59 were identified as relevant (figure 1), and 43 studies were included in our analysis (table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The outcomes in each of these studies were different, but leakage between products was similar in three studies and significantly less among menstrual cups for one study (figure 2).23 In studies that assessed menstrual cups that are still available, the proportion of leakage among the participants who reported use of the menstrual cup was 2–31% for a wide range of definitions, as shown in figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Some factors mentioned in association with leakage by study authors included menorrhagia,48 unusual anatomy of the uterus,53 need for a larger size of menstrual cup,5 and incorrect placement of the menstrual cup, or that it had filled to capacity.39, 53\nFigure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Safety and side-effects of the menstrual cup\n\n\n\n\nn (%) or description\nNotes\nData source\n\n\nHandling and positioning of menstrual cup\nVaginal wound\n\n\nCup not clear (Divacup or softcup)\nEvent April, 2012; vaginal wound due to use of menstrual cup, needing treatment from physician for vaginal bleeding\nComplete medical records were not available for evaluation\nFDA database14\n\n\n\n\nSoftcup (cervical)\nReported April, 2012; long-term customer of softcup product claimed vaginal scarring due to use\nMedical director did not find anything in medical records provided by customer related to vaginal health\nFDA database14\n\n\n\n\nSoftcup (cervical)\nFDA database case report: “…cup wore through the vaginal wall, damaging an artery that required surgical repair”\nEvent could not be confirmed; no medical records were available\nNorth et al (2011)13\n\n\nVaginal pain on removal\n\n\nDivacup (vaginal)\nEvent March, 2017; extreme pain on removal (first use), individual stopped using the cup\nSelf-report; no medical report available\nFDA database14\n\n\nPelvic pain\n\n\nSoftcup (cervical)\nEvent February, 2017; pain in lower pelvis and rectum and nausea about 1 h after insertion, no longer present approximately 30 min after removal\nSelf-report; no medical evaluation available; individual stopped use after trying twice (possibly vascular compression)\nFDA database14\n\n\nVaginal irritation\n\n\nGynaeseal (cervical)\nOne (1%) of 73\nSelf-report by participant\nCattanach et al (1991)39\n\n\n\n\nCervix irritation\n\n\n\nMenses cup (vaginal)\nOne (2%) of 51\nCervical smear was normal\nCheng et al (1995)41\n\n\nAllergy and rash\n\n\nNR, vaginal cup\nAllergy: one (1%) of 150; and rash: two (1%) of 150\n· ·\nKakani et al (2017)48\n\n\n\n\nSoftcup (cervical)\nFDA database: two case reports\nNR\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nEvent 2010: silicone allergy in one individual\nSurgery was needed for vaginal repair; manufacturer noted that silicone allergy is very rare\nFDA database14\n\n\nDifficulty with removal requiring professional assistance\n\n\nGynaeseal (cervical)\nOne (5%) of 22\n· ·\nGleeson et al (1993)46\n\n\n\n\nSoftcup (cervical)\nFDA database: three case reports reported by North 2011; one event in 2018\n· ·\nNorth et al (2011),13 FDA database14\n\n\n\n\nSoftcup (cervical)\nReported complaints to company 2003–08: 42 individuals underwent physician-assisted removal\nOther complaints reported to company included poor fit (n=102), leakage (n=168), messy (n=98)\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nCase report: menstrual cup lodged on cervix, difficult to remove, requiring assistance\nModerate cervical inflammation after retrieval\nDay et al (2012)63\n\n\n\n\nDivacup (vaginal)\nEvent April, 2015: one case report required an emergency room visit for removal\n· ·\nFDA database14\n\n\nReproductive tract observations with use of menstrual cup\nVulva abnormalities\n\n\nSoftcup (cervical)\nBaseline: four (1%) of 393; cycle 1: eight (2%) of 365; cycle 2: six (2%) of 326; cycle 3: five (2%) of 305\nVulva-vaginal inspection at baseline and monthly for 3 months; no p values reported\nNorth et al (2011)13\n\n\nAbnormalities of vaginal wall\n\n\nSoftcup (cervical)\nZero of 44\nVulva-vaginal inspection at baseline and monthly for 3 months\nNorth et al (2011)13\n\n\n\n\nTassette (vaginal)\nZero of 12\nVaginal inspection after 3 months\nPena et al (1962)52\n\n\n\n\nTassette (vaginal)\nZero of 50\nVaginal inspection done; timing of inspections not clear\nKarnaky et al (1962)70\n\n\nAbnormalities of cervix\n\n\nSoftcup (cervical)\nBaseline: 23 (6%) of 390; cycle 1: ten (3%) of 345; cycle 2: six (2%) of 326; cycle 3: four (1%) of 300\nInspection of cervix; no p values reported for differences\nNorth et al (2011)13\n\n\n\n\nSoftcup (cervical)\nAbnormal cervical smear test: baseline: one (<1%) of 406; cycle 1: one (<1%) of 368; cycle 2: two (1%) of 329; cycle 3: zero of 308\nAbnormal cervical smear test results were exclusion criteria at admission, and a reason for discontinuation of the study; no p values reported for differences\nNorth et al (2011)13\n\n\nCondition of vaginal and cervical epithelium\n\n\nSoftcup (cervical)\n44 women examined at baseline, 37 at 2–3 months, and 25 at 5–6 months\n“The Softcup caused no alteration or disruption in vaginal or cervical epithelium, as assessed by colposcopy and cervical cytology”\nNorth et al (2011)13\n\n\nVaginal flora and infections with use of menstrual cup\npH changes of vagina\n\n\nTassette (vaginal)\nZero of 50\nNo abnormalities, vaginal areas where menstrual cup was placed were more acid\nKarnaky et al (1962)70\n\n\n\n\nSoftcup (cervical)\nMean pH at baseline: 4·6 (n=400); cycle 1: 4·6 (n=368); cycle 2: 4·6 (n=329); cycle 3: 4·5 (n=308)\nNo p values reported\nNorth et al (2011)13\n\n\nClue cells (vaginal smear) Lactobaccilus\n\n\nSoftcup (cervical)\nNumber with clue cells: baseline n=6; cycle 1 n=6; cycle 2 n=2; cycle 3 n=4\nSample sizes and p values were not reported\nNorth et al (2011)13\n\n\nLactobaccilus\n\n\nSoftcup (cervical)\n“…before, during, and after use of the cup, vaginal Lactobacillus (normal vaginal flora) was maintained at normal levels.”\nData in figure 3 in publication cannot be extracted; no significant changes according to authors\nNorth et al (2011)13\n\n\nGardnerella vaginalis\n\n\nSoftcup (cervical)\nNo significant changes from baseline-cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nBacterial vaginosis\n\n\nSoftcup (cervical)\nNo significant changes from baseline to cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup 21 (15%) of 144; pads 40 (20%) of 202, and usual practice (control) 32 (21%) of 156; cup vs control p=0·11 and cup vs pads p=0·13; among girls enrolled for ≥9 months: cup 13 (13%) of 101, pads 29 (20%) of 143, usual practice 20 (19%) of 104; cup vs control p=0·07, and cup vs pads p=0·018\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nCandidiasis\n\n\nSoftcup (cervical)\nNumber with candidiasis: baseline n=6; cycle 1 n=6; cycle 2 n=3; cycle 3 n=6\nSample sizes not reported; according to authors, yeast decreased significantly from month 1 to 2\nNorth et al (2011)13\n\n\n\n\nRuby cup (vaginal)\nZero of 18 participants had vaginal candidiasis at follow-up (3–5 months)\nNA\nTellier et al (2012)56\n\n\n\n\nTassette (vaginal)\n\nCandida albicans decreased with the use of the cup\nNR\nKarnaky et al (1962)70\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup 11 (8%) of 143, pads 19 (10%) of 200, usual practice (control) 13 (9%) of 156; cup vs control p=0·87, and cup vs pads p=0·68\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nGroup B Streptococcus\n\n\nSoftcup (cervical)\nNo differences between baseline and cycle 1 to cycle 3\nData in figure 3 in publication cannot be extracted; no significant changes according to authors\nNorth et al (2011)13\n\n\nEnterococcus\n\n\nSoftcup (cervical)\nIncrease in Enterococcus from cycle 2 to cycle 3 (p=0·03)\n“… this increased frequency persisted for 3 months after discontinuing use of the cup, suggesting that factors or behavior other than cup use may have influenced colonization”; data in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nE coli\n\n\nSoftcup (cervical)\nNo significant changes from baseline to cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nEscherichia coli on menstrual cup\n\n\nMooncup (vaginal)\nNine (53%) of 17 if used cup for <6 months; four (22%) of 18 if used for ≥6 months (p=0·12); association between E coli with heavy periods: 61·5% of girls reporting heavy periods had E coli on cups, compared with 22·7% of those stating they did not have heavy periods (p=0·022, no numbers presented)\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nJuma et al (2017)29\n\n\nChlamydia trachomatis\n\n\nMooncup (vaginal)\nStudy end survey: cup three (2%) of 144, pads three (2%) of 201, usual practice (control) seven (5%) of 154; cup vs control p=0·20, and cup vs pads p=0·63\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nTrichomonas vaginalis\n\n\nSoftcup (cervical)\nZero cases at baseline, and cycles 1 to 3\nSample sizes not reported\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup two (1%) of 143, pads five (3%) of 200, usual practice (control) seven (5%) of 154; cup vs control p=0·12, and cup vs pads p=0·36\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\n\n\nRuby cup (vaginal)\nZero of 18 at baseline, and at 3–5 months of follow-up\nNA\nTellier et al (2012)56\n\n\nNeisseria gonorrhoea\n\n\nMooncup (vaginal)\nStudy end survey: cup one (1%) of 144, pads one (1%) of 201, usual practice (control) one (1%) of 154; cup vs control p=0·96, and cup vs pads p=0·81\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\n\n\nRuby cup (vaginal)\nZero of 18 at baseline, and at 3–5 months of follow-up\nNA\nTellier et al (2012)56\n\n\nStaphylococcus aureus\n\n\nSoftcup (cervical)\nNo significant changes in cycles 1–3 compared with baseline\nData in figure 3 of publication cannot be extracted\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nAmong menstrual cup users: four (11%) of 38 in first month of intervention, 13 (9%) of 139 after first month; p=0·83 (median follow-up 4 months, range 2–11 for this substudy); prevalence was 21 (11%) of 197 in sanitary pads group, and 16 (11%) of 153 in usual practice group\nCluster randomised trial in schools; median follow-up 11 months (range 3–15); samples from vaginal swab (self-swabbing)\nJuma et al (2017)29\n\n\n\n\nbe'Cup (vaginal)\nSilicone cup: potentially more S aureus after incubation for 8 h with shaking in a plastic bag with S aureus in one of two cups used, but not when no shaking\nIn-vitro study\nNonfoux et al (2018)73\n\n\n\n\nMe Luna (vaginal)\nThermoplastic isomer cup: no more S aureus after incubation for 8 h with shaking in plastic sac, and not when no shaking\nIn-vitro study\nNonfoux et al (2018)73\n\n\nTSST-1\n\n\nMooncup (vaginal)\n49 schoolgirls with vaginal S aureus had second swab: ten yielded S aureus, two had TSST-1, both in sanitary pad group; the cases were asymptomatic\nCluster randomised trial in schools; median follow-up 11 months (range 3–15); sample from vaginal swab (self-swabbing)\nJuma et al (2017)29\n\n\n\n\nNR\nNo TSST-1 in supernatant of S aureus cultivated for 24 h (incubated aerobically in a still growth environment) in the presence of elastic polymer menstrual cup (n=16 menstrual cups)\nIn-vitro study\nTierno et al (1989)71\n\n\n\n\nTassaway (vaginal)\n\nS aureus MN8 produced no TSST-1 when grown in the presence of Tassaway (elastomeric polymer, n=6), washed or unwashed, no shaking, incubation overnight\nIn-vitro study\nTierno at al (1994)72\n\n\n\n\nbe'Cup (vaginal)\nSilicone cup: potentially more TSST-1 production after incubation for 8 h with shaking in plastic bag with S aureus compared with control, but not when not shaken or with pieces of cup\nIn-vitro study\nNonfoux et al (2018)73\n\n\n\n\nMe Luna (vaginal)\nThermoplastic isomer cup: potentially more TSST-1 production after incubation for 8 h with shaking in plastic bag with S aureus compared with control, but not when not shaken or with pieces of cup\nIn-vitro study\nNonfoux et al (2018)73\n\n\nTSS\n\n\nMooncup (vaginal)\nZero of 192 in trial in Kenya\n“Safety monitoring components comprised routine nurse-based screening, population-based monitoring (school and community) and clinical evaluation of infection with laboratory confirmation”\nJuma et al (2017)29\n\n\n\n\nSoftcup (cervical)\nTwo case reports in the FDA database\nBoth unconfirmed cases of TSS\nNorth et al (2011)13\n\n\n\n\nDivacup (vaginal)\nOne case report: blood cultures and urine culture negative, no culture of the menstrual cup was done\nWoman had history of Hashimoto's thyroiditis and chronic menorrhagia\nMitchell et al (2015)66\n\n\n\n\nMooncup (vaginal)\nEvent February, 2012: TSS 2 days after using of first and new Mooncup resulting in 9 days of inpatient hospital stay; vaginal swab positive for S aureus\n\nHad an IUD, Mooncup was not sent for bacteriological testing\nFDA database14\n\n\n\n\nDivacup (vaginal)\nEvent February, 2015: TSS from Streptococcus resulting in 5 days of i-patient hospital stay; culture of cup isolated group A and B streptococcus\n\nWoman had used Divacup for menstrual period, which started 3 days before illness; menstrual cup was in for 18 h on admission to hospital\nFDA database14\n\n\nUTI\n\n\nRuby cup (vaginal)\nBaseline: four (13%) of 31; at follow-up (after 3–5 months) three (17%) of 18; p=0·65, McNemar test\nOne participant with a UTI at enrolment and follow-up had her cup stolen and used toilet paper in vagina as a tampon\nTellier et al (2012)56\n\n\n\n\nGynaeseal (cervical)\nOne (1%) of 73 had transient dysuria\n“The woman who developed dysuria did not seek treatment and the problem subsided within 24–48 hours”\nCattanach et al (1991)39\n\n\n\n\nSoftcup (cervical)\nUrine analysis done; detailed results not reported\n“Monthly monitoring of gynecological health via urinalysis, pelvic examination with visual evaluation of tissues, vaginal pH, and microscopic wet mount showed no adverse effects of cup use”\nNorth et al (2011)13\n\n\n\n\nSoftcup (cervical)\nEvent August, 2014: UTI confirmed by urine cultures twice after use of softcup\nMedical records were not available for evaluation\nFDA database14\n\n\nInfections overall\n\n\nTassette (vaginal)\n“The amount of bacterial contamination was greatest with the pad, next with the tampon and least with the rubber cup”\nNo data provided; study reported to make cultures from vaginal wall samples and to examine fresh and stained smears for C albicans, Trichomonas vaginalis, Haemophilus vaginalis, and for predominance of Gram-positive or Gram-negative cocci, small rods or long-rod bacilli (Doederlein bacilli)\nKarnaky et al (1962)70\n\n\n\n\nSoftcup (cervical)\nFDA database: one case report\nVaginal infection not further specified; could not be confirmed at follow-up\nNorth et al (2011)13\n\n\n\n\nButterfly cup (vaginal)\n“…none of the women sought treatment for a pelvic infection.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In India22 and Tanzania,43 the uptake of menstrual cups was significantly slower than uptake of pads (appendix p 24).22, 43 In 15 studies with relevant information, 73% (pooled estimate: n=1144, 95% CI 59–84; I2=96%) of participants reported willingness to continue use of the menstrual cup after the study (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The corresponding author had full access to all data in the study and had final responsibility to submit for publication.Results\nOf 436 unique records identified (appendix p 6), 59 were identified as relevant (figure 1), and 43 studies were included in our analysis (table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The outcomes in each of these studies were different, but leakage between products was similar in three studies and significantly less among menstrual cups for one study (figure 2).23 In studies that assessed menstrual cups that are still available, the proportion of leakage among the participants who reported use of the menstrual cup was 2–31% for a wide range of definitions, as shown in figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Some factors mentioned in association with leakage by study authors included menorrhagia,48 unusual anatomy of the uterus,53 need for a larger size of menstrual cup,5 and incorrect placement of the menstrual cup, or that it had filled to capacity.39, 53\nFigure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Safety and side-effects of the menstrual cup\n\n\n\n\nn (%) or description\nNotes\nData source\n\n\nHandling and positioning of menstrual cup\nVaginal wound\n\n\nCup not clear (Divacup or softcup)\nEvent April, 2012; vaginal wound due to use of menstrual cup, needing treatment from physician for vaginal bleeding\nComplete medical records were not available for evaluation\nFDA database14\n\n\n\n\nSoftcup (cervical)\nReported April, 2012; long-term customer of softcup product claimed vaginal scarring due to use\nMedical director did not find anything in medical records provided by customer related to vaginal health\nFDA database14\n\n\n\n\nSoftcup (cervical)\nFDA database case report: “…cup wore through the vaginal wall, damaging an artery that required surgical repair”\nEvent could not be confirmed; no medical records were available\nNorth et al (2011)13\n\n\nVaginal pain on removal\n\n\nDivacup (vaginal)\nEvent March, 2017; extreme pain on removal (first use), individual stopped using the cup\nSelf-report; no medical report available\nFDA database14\n\n\nPelvic pain\n\n\nSoftcup (cervical)\nEvent February, 2017; pain in lower pelvis and rectum and nausea about 1 h after insertion, no longer present approximately 30 min after removal\nSelf-report; no medical evaluation available; individual stopped use after trying twice (possibly vascular compression)\nFDA database14\n\n\nVaginal irritation\n\n\nGynaeseal (cervical)\nOne (1%) of 73\nSelf-report by participant\nCattanach et al (1991)39\n\n\n\n\nCervix irritation\n\n\n\nMenses cup (vaginal)\nOne (2%) of 51\nCervical smear was normal\nCheng et al (1995)41\n\n\nAllergy and rash\n\n\nNR, vaginal cup\nAllergy: one (1%) of 150; and rash: two (1%) of 150\n· ·\nKakani et al (2017)48\n\n\n\n\nSoftcup (cervical)\nFDA database: two case reports\nNR\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nEvent 2010: silicone allergy in one individual\nSurgery was needed for vaginal repair; manufacturer noted that silicone allergy is very rare\nFDA database14\n\n\nDifficulty with removal requiring professional assistance\n\n\nGynaeseal (cervical)\nOne (5%) of 22\n· ·\nGleeson et al (1993)46\n\n\n\n\nSoftcup (cervical)\nFDA database: three case reports reported by North 2011; one event in 2018\n· ·\nNorth et al (2011),13 FDA database14\n\n\n\n\nSoftcup (cervical)\nReported complaints to company 2003–08: 42 individuals underwent physician-assisted removal\nOther complaints reported to company included poor fit (n=102), leakage (n=168), messy (n=98)\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nCase report: menstrual cup lodged on cervix, difficult to remove, requiring assistance\nModerate cervical inflammation after retrieval\nDay et al (2012)63\n\n\n\n\nDivacup (vaginal)\nEvent April, 2015: one case report required an emergency room visit for removal\n· ·\nFDA database14\n\n\nReproductive tract observations with use of menstrual cup\nVulva abnormalities\n\n\nSoftcup (cervical)\nBaseline: four (1%) of 393; cycle 1: eight (2%) of 365; cycle 2: six (2%) of 326; cycle 3: five (2%) of 305\nVulva-vaginal inspection at baseline and monthly for 3 months; no p values reported\nNorth et al (2011)13\n\n\nAbnormalities of vaginal wall\n\n\nSoftcup (cervical)\nZero of 44\nVulva-vaginal inspection at baseline and monthly for 3 months\nNorth et al (2011)13\n\n\n\n\nTassette (vaginal)\nZero of 12\nVaginal inspection after 3 months\nPena et al (1962)52\n\n\n\n\nTassette (vaginal)\nZero of 50\nVaginal inspection done; timing of inspections not clear\nKarnaky et al (1962)70\n\n\nAbnormalities of cervix\n\n\nSoftcup (cervical)\nBaseline: 23 (6%) of 390; cycle 1: ten (3%) of 345; cycle 2: six (2%) of 326; cycle 3: four (1%) of 300\nInspection of cervix; no p values reported for differences\nNorth et al (2011)13\n\n\n\n\nSoftcup (cervical)\nAbnormal cervical smear test: baseline: one (<1%) of 406; cycle 1: one (<1%) of 368; cycle 2: two (1%) of 329; cycle 3: zero of 308\nAbnormal cervical smear test results were exclusion criteria at admission, and a reason for discontinuation of the study; no p values reported for differences\nNorth et al (2011)13\n\n\nCondition of vaginal and cervical epithelium\n\n\nSoftcup (cervical)\n44 women examined at baseline, 37 at 2–3 months, and 25 at 5–6 months\n“The Softcup caused no alteration or disruption in vaginal or cervical epithelium, as assessed by colposcopy and cervical cytology”\nNorth et al (2011)13\n\n\nVaginal flora and infections with use of menstrual cup\npH changes of vagina\n\n\nTassette (vaginal)\nZero of 50\nNo abnormalities, vaginal areas where menstrual cup was placed were more acid\nKarnaky et al (1962)70\n\n\n\n\nSoftcup (cervical)\nMean pH at baseline: 4·6 (n=400); cycle 1: 4·6 (n=368); cycle 2: 4·6 (n=329); cycle 3: 4·5 (n=308)\nNo p values reported\nNorth et al (2011)13\n\n\nClue cells (vaginal smear) Lactobaccilus\n\n\nSoftcup (cervical)\nNumber with clue cells: baseline n=6; cycle 1 n=6; cycle 2 n=2; cycle 3 n=4\nSample sizes and p values were not reported\nNorth et al (2011)13\n\n\nLactobaccilus\n\n\nSoftcup (cervical)\n“…before, during, and after use of the cup, vaginal Lactobacillus (normal vaginal flora) was maintained at normal levels.”\nData in figure 3 in publication cannot be extracted; no significant changes according to authors\nNorth et al (2011)13\n\n\nGardnerella vaginalis\n\n\nSoftcup (cervical)\nNo significant changes from baseline-cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nBacterial vaginosis\n\n\nSoftcup (cervical)\nNo significant changes from baseline to cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup 21 (15%) of 144; pads 40 (20%) of 202, and usual practice (control) 32 (21%) of 156; cup vs control p=0·11 and cup vs pads p=0·13; among girls enrolled for ≥9 months: cup 13 (13%) of 101, pads 29 (20%) of 143, usual practice 20 (19%) of 104; cup vs control p=0·07, and cup vs pads p=0·018\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nCandidiasis\n\n\nSoftcup (cervical)\nNumber with candidiasis: baseline n=6; cycle 1 n=6; cycle 2 n=3; cycle 3 n=6\nSample sizes not reported; according to authors, yeast decreased significantly from month 1 to 2\nNorth et al (2011)13\n\n\n\n\nRuby cup (vaginal)\nZero of 18 participants had vaginal candidiasis at follow-up (3–5 months)\nNA\nTellier et al (2012)56\n\n\n\n\nTassette (vaginal)\n\nCandida albicans decreased with the use of the cup\nNR\nKarnaky et al (1962)70\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup 11 (8%) of 143, pads 19 (10%) of 200, usual practice (control) 13 (9%) of 156; cup vs control p=0·87, and cup vs pads p=0·68\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nGroup B Streptococcus\n\n\nSoftcup (cervical)\nNo differences between baseline and cycle 1 to cycle 3\nData in figure 3 in publication cannot be extracted; no significant changes according to authors\nNorth et al (2011)13\n\n\nEnterococcus\n\n\nSoftcup (cervical)\nIncrease in Enterococcus from cycle 2 to cycle 3 (p=0·03)\n“… this increased frequency persisted for 3 months after discontinuing use of the cup, suggesting that factors or behavior other than cup use may have influenced colonization”; data in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nE coli\n\n\nSoftcup (cervical)\nNo significant changes from baseline to cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nEscherichia coli on menstrual cup\n\n\nMooncup (vaginal)\nNine (53%) of 17 if used cup for <6 months; four (22%) of 18 if used for ≥6 months (p=0·12); association between E coli with heavy periods: 61·5% of girls reporting heavy periods had E coli on cups, compared with 22·7% of those stating they did not have heavy periods (p=0·022, no numbers presented)\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nJuma et al (2017)29\n\n\nChlamydia trachomatis\n\n\nMooncup (vaginal)\nStudy end survey: cup three (2%) of 144, pads three (2%) of 201, usual practice (control) seven (5%) of 154; cup vs control p=0·20, and cup vs pads p=0·63\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nTrichomonas vaginalis\n\n\nSoftcup (cervical)\nZero cases at baseline, and cycles 1 to 3\nSample sizes not reported\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup two (1%) of 143, pads five (3%) of 200, usual practice (control) seven (5%) of 154; cup vs control p=0·12, and cup vs pads p=0·36\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\n\n\nRuby cup (vaginal)\nZero of 18 at baseline, and at 3–5 months of follow-up\nNA\nTellier et al (2012)56\n\n\nNeisseria gonorrhoea\n\n\nMooncup (vaginal)\nStudy end survey: cup one (1%) of 144, pads one (1%) of 201, usual practice (control) one (1%) of 154; cup vs control p=0·96, and cup vs pads p=0·81\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\n\n\nRuby cup (vaginal)\nZero of 18 at baseline, and at 3–5 months of follow-up\nNA\nTellier et al (2012)56\n\n\nStaphylococcus aureus\n\n\nSoftcup (cervical)\nNo significant changes in cycles 1–3 compared with baseline\nData in figure 3 of publication cannot be extracted\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nAmong menstrual cup users: four (11%) of 38 in first month of intervention, 13 (9%) of 139 after first month; p=0·83 (median follow-up 4 months, range 2–11 for this substudy); prevalence was 21 (11%) of 197 in sanitary pads group, and 16 (11%) of 153 in usual practice group\nCluster randomised trial in schools; median follow-up 11 months (range 3–15); samples from vaginal swab (self-swabbing)\nJuma et al (2017)29\n\n\n\n\nbe'Cup (vaginal)\nSilicone cup: potentially more S aureus after incubation for 8 h with shaking in a plastic bag with S aureus in one of two cups used, but not when no shaking\nIn-vitro study\nNonfoux et al (2018)73\n\n\n\n\nMe Luna (vaginal)\nThermoplastic isomer cup: no more S aureus after incubation for 8 h with shaking in plastic sac, and not when no shaking\nIn-vitro study\nNonfoux et al (2018)73\n\n\nTSST-1\n\n\nMooncup (vaginal)\n49 schoolgirls with vaginal S aureus had second swab: ten yielded S aureus, two had TSST-1, both in sanitary pad group; the cases were asymptomatic\nCluster randomised trial in schools; median follow-up 11 months (range 3–15); sample from vaginal swab (self-swabbing)\nJuma et al (2017)29\n\n\n\n\nNR\nNo TSST-1 in supernatant of S aureus cultivated for 24 h (incubated aerobically in a still growth environment) in the presence of elastic polymer menstrual cup (n=16 menstrual cups)\nIn-vitro study\nTierno et al (1989)71\n\n\n\n\nTassaway (vaginal)\n\nS aureus MN8 produced no TSST-1 when grown in the presence of Tassaway (elastomeric polymer, n=6), washed or unwashed, no shaking, incubation overnight\nIn-vitro study\nTierno at al (1994)72\n\n\n\n\nbe'Cup (vaginal)\nSilicone cup: potentially more TSST-1 production after incubation for 8 h with shaking in plastic bag with S aureus compared with control, but not when not shaken or with pieces of cup\nIn-vitro study\nNonfoux et al (2018)73\n\n\n\n\nMe Luna (vaginal)\nThermoplastic isomer cup: potentially more TSST-1 production after incubation for 8 h with shaking in plastic bag with S aureus compared with control, but not when not shaken or with pieces of cup\nIn-vitro study\nNonfoux et al (2018)73\n\n\nTSS\n\n\nMooncup (vaginal)\nZero of 192 in trial in Kenya\n“Safety monitoring components comprised routine nurse-based screening, population-based monitoring (school and community) and clinical evaluation of infection with laboratory confirmation”\nJuma et al (2017)29\n\n\n\n\nSoftcup (cervical)\nTwo case reports in the FDA database\nBoth unconfirmed cases of TSS\nNorth et al (2011)13\n\n\n\n\nDivacup (vaginal)\nOne case report: blood cultures and urine culture negative, no culture of the menstrual cup was done\nWoman had history of Hashimoto's thyroiditis and chronic menorrhagia\nMitchell et al (2015)66\n\n\n\n\nMooncup (vaginal)\nEvent February, 2012: TSS 2 days after using of first and new Mooncup resulting in 9 days of inpatient hospital stay; vaginal swab positive for S aureus\n\nHad an IUD, Mooncup was not sent for bacteriological testing\nFDA database14\n\n\n\n\nDivacup (vaginal)\nEvent February, 2015: TSS from Streptococcus resulting in 5 days of i-patient hospital stay; culture of cup isolated group A and B streptococcus\n\nWoman had used Divacup for menstrual period, which started 3 days before illness; menstrual cup was in for 18 h on admission to hospital\nFDA database14\n\n\nUTI\n\n\nRuby cup (vaginal)\nBaseline: four (13%) of 31; at follow-up (after 3–5 months) three (17%) of 18; p=0·65, McNemar test\nOne participant with a UTI at enrolment and follow-up had her cup stolen and used toilet paper in vagina as a tampon\nTellier et al (2012)56\n\n\n\n\nGynaeseal (cervical)\nOne (1%) of 73 had transient dysuria\n“The woman who developed dysuria did not seek treatment and the problem subsided within 24–48 hours”\nCattanach et al (1991)39\n\n\n\n\nSoftcup (cervical)\nUrine analysis done; detailed results not reported\n“Monthly monitoring of gynecological health via urinalysis, pelvic examination with visual evaluation of tissues, vaginal pH, and microscopic wet mount showed no adverse effects of cup use”\nNorth et al (2011)13\n\n\n\n\nSoftcup (cervical)\nEvent August, 2014: UTI confirmed by urine cultures twice after use of softcup\nMedical records were not available for evaluation\nFDA database14\n\n\nInfections overall\n\n\nTassette (vaginal)\n“The amount of bacterial contamination was greatest with the pad, next with the tampon and least with the rubber cup”\nNo data provided; study reported to make cultures from vaginal wall samples and to examine fresh and stained smears for C albicans, Trichomonas vaginalis, Haemophilus vaginalis, and for predominance of Gram-positive or Gram-negative cocci, small rods or long-rod bacilli (Doederlein bacilli)\nKarnaky et al (1962)70\n\n\n\n\nSoftcup (cervical)\nFDA database: one case report\nVaginal infection not further specified; could not be confirmed at follow-up\nNorth et al (2011)13\n\n\n\n\nButterfly cup (vaginal)\n“…none of the women sought treatment for a pelvic infection.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In India22 and Tanzania,43 the uptake of menstrual cups was significantly slower than uptake of pads (appendix p 24).22, 43 In 15 studies with relevant information, 73% (pooled estimate: n=1144, 95% CI 59–84; I2=96%) of participants reported willingness to continue use of the menstrual cup after the study (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The corresponding author had full access to all data in the study and had final responsibility to submit for publication.Results\nOf 436 unique records identified (appendix p 6), 59 were identified as relevant (figure 1), and 43 studies were included in our analysis (table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The outcomes in each of these studies were different, but leakage between products was similar in three studies and significantly less among menstrual cups for one study (figure 2).23 In studies that assessed menstrual cups that are still available, the proportion of leakage among the participants who reported use of the menstrual cup was 2–31% for a wide range of definitions, as shown in figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Some factors mentioned in association with leakage by study authors included menorrhagia,48 unusual anatomy of the uterus,53 need for a larger size of menstrual cup,5 and incorrect placement of the menstrual cup, or that it had filled to capacity.39, 53\nFigure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Safety and side-effects of the menstrual cup\n\n\n\n\nn (%) or description\nNotes\nData source\n\n\nHandling and positioning of menstrual cup\nVaginal wound\n\n\nCup not clear (Divacup or softcup)\nEvent April, 2012; vaginal wound due to use of menstrual cup, needing treatment from physician for vaginal bleeding\nComplete medical records were not available for evaluation\nFDA database14\n\n\n\n\nSoftcup (cervical)\nReported April, 2012; long-term customer of softcup product claimed vaginal scarring due to use\nMedical director did not find anything in medical records provided by customer related to vaginal health\nFDA database14\n\n\n\n\nSoftcup (cervical)\nFDA database case report: “…cup wore through the vaginal wall, damaging an artery that required surgical repair”\nEvent could not be confirmed; no medical records were available\nNorth et al (2011)13\n\n\nVaginal pain on removal\n\n\nDivacup (vaginal)\nEvent March, 2017; extreme pain on removal (first use), individual stopped using the cup\nSelf-report; no medical report available\nFDA database14\n\n\nPelvic pain\n\n\nSoftcup (cervical)\nEvent February, 2017; pain in lower pelvis and rectum and nausea about 1 h after insertion, no longer present approximately 30 min after removal\nSelf-report; no medical evaluation available; individual stopped use after trying twice (possibly vascular compression)\nFDA database14\n\n\nVaginal irritation\n\n\nGynaeseal (cervical)\nOne (1%) of 73\nSelf-report by participant\nCattanach et al (1991)39\n\n\n\n\nCervix irritation\n\n\n\nMenses cup (vaginal)\nOne (2%) of 51\nCervical smear was normal\nCheng et al (1995)41\n\n\nAllergy and rash\n\n\nNR, vaginal cup\nAllergy: one (1%) of 150; and rash: two (1%) of 150\n· ·\nKakani et al (2017)48\n\n\n\n\nSoftcup (cervical)\nFDA database: two case reports\nNR\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nEvent 2010: silicone allergy in one individual\nSurgery was needed for vaginal repair; manufacturer noted that silicone allergy is very rare\nFDA database14\n\n\nDifficulty with removal requiring professional assistance\n\n\nGynaeseal (cervical)\nOne (5%) of 22\n· ·\nGleeson et al (1993)46\n\n\n\n\nSoftcup (cervical)\nFDA database: three case reports reported by North 2011; one event in 2018\n· ·\nNorth et al (2011),13 FDA database14\n\n\n\n\nSoftcup (cervical)\nReported complaints to company 2003–08: 42 individuals underwent physician-assisted removal\nOther complaints reported to company included poor fit (n=102), leakage (n=168), messy (n=98)\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nCase report: menstrual cup lodged on cervix, difficult to remove, requiring assistance\nModerate cervical inflammation after retrieval\nDay et al (2012)63\n\n\n\n\nDivacup (vaginal)\nEvent April, 2015: one case report required an emergency room visit for removal\n· ·\nFDA database14\n\n\nReproductive tract observations with use of menstrual cup\nVulva abnormalities\n\n\nSoftcup (cervical)\nBaseline: four (1%) of 393; cycle 1: eight (2%) of 365; cycle 2: six (2%) of 326; cycle 3: five (2%) of 305\nVulva-vaginal inspection at baseline and monthly for 3 months; no p values reported\nNorth et al (2011)13\n\n\nAbnormalities of vaginal wall\n\n\nSoftcup (cervical)\nZero of 44\nVulva-vaginal inspection at baseline and monthly for 3 months\nNorth et al (2011)13\n\n\n\n\nTassette (vaginal)\nZero of 12\nVaginal inspection after 3 months\nPena et al (1962)52\n\n\n\n\nTassette (vaginal)\nZero of 50\nVaginal inspection done; timing of inspections not clear\nKarnaky et al (1962)70\n\n\nAbnormalities of cervix\n\n\nSoftcup (cervical)\nBaseline: 23 (6%) of 390; cycle 1: ten (3%) of 345; cycle 2: six (2%) of 326; cycle 3: four (1%) of 300\nInspection of cervix; no p values reported for differences\nNorth et al (2011)13\n\n\n\n\nSoftcup (cervical)\nAbnormal cervical smear test: baseline: one (<1%) of 406; cycle 1: one (<1%) of 368; cycle 2: two (1%) of 329; cycle 3: zero of 308\nAbnormal cervical smear test results were exclusion criteria at admission, and a reason for discontinuation of the study; no p values reported for differences\nNorth et al (2011)13\n\n\nCondition of vaginal and cervical epithelium\n\n\nSoftcup (cervical)\n44 women examined at baseline, 37 at 2–3 months, and 25 at 5–6 months\n“The Softcup caused no alteration or disruption in vaginal or cervical epithelium, as assessed by colposcopy and cervical cytology”\nNorth et al (2011)13\n\n\nVaginal flora and infections with use of menstrual cup\npH changes of vagina\n\n\nTassette (vaginal)\nZero of 50\nNo abnormalities, vaginal areas where menstrual cup was placed were more acid\nKarnaky et al (1962)70\n\n\n\n\nSoftcup (cervical)\nMean pH at baseline: 4·6 (n=400); cycle 1: 4·6 (n=368); cycle 2: 4·6 (n=329); cycle 3: 4·5 (n=308)\nNo p values reported\nNorth et al (2011)13\n\n\nClue cells (vaginal smear) Lactobaccilus\n\n\nSoftcup (cervical)\nNumber with clue cells: baseline n=6; cycle 1 n=6; cycle 2 n=2; cycle 3 n=4\nSample sizes and p values were not reported\nNorth et al (2011)13\n\n\nLactobaccilus\n\n\nSoftcup (cervical)\n“…before, during, and after use of the cup, vaginal Lactobacillus (normal vaginal flora) was maintained at normal levels.”\nData in figure 3 in publication cannot be extracted; no significant changes according to authors\nNorth et al (2011)13\n\n\nGardnerella vaginalis\n\n\nSoftcup (cervical)\nNo significant changes from baseline-cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nBacterial vaginosis\n\n\nSoftcup (cervical)\nNo significant changes from baseline to cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup 21 (15%) of 144; pads 40 (20%) of 202, and usual practice (control) 32 (21%) of 156; cup vs control p=0·11 and cup vs pads p=0·13; among girls enrolled for ≥9 months: cup 13 (13%) of 101, pads 29 (20%) of 143, usual practice 20 (19%) of 104; cup vs control p=0·07, and cup vs pads p=0·018\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nCandidiasis\n\n\nSoftcup (cervical)\nNumber with candidiasis: baseline n=6; cycle 1 n=6; cycle 2 n=3; cycle 3 n=6\nSample sizes not reported; according to authors, yeast decreased significantly from month 1 to 2\nNorth et al (2011)13\n\n\n\n\nRuby cup (vaginal)\nZero of 18 participants had vaginal candidiasis at follow-up (3–5 months)\nNA\nTellier et al (2012)56\n\n\n\n\nTassette (vaginal)\n\nCandida albicans decreased with the use of the cup\nNR\nKarnaky et al (1962)70\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup 11 (8%) of 143, pads 19 (10%) of 200, usual practice (control) 13 (9%) of 156; cup vs control p=0·87, and cup vs pads p=0·68\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nGroup B Streptococcus\n\n\nSoftcup (cervical)\nNo differences between baseline and cycle 1 to cycle 3\nData in figure 3 in publication cannot be extracted; no significant changes according to authors\nNorth et al (2011)13\n\n\nEnterococcus\n\n\nSoftcup (cervical)\nIncrease in Enterococcus from cycle 2 to cycle 3 (p=0·03)\n“… this increased frequency persisted for 3 months after discontinuing use of the cup, suggesting that factors or behavior other than cup use may have influenced colonization”; data in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nE coli\n\n\nSoftcup (cervical)\nNo significant changes from baseline to cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nEscherichia coli on menstrual cup\n\n\nMooncup (vaginal)\nNine (53%) of 17 if used cup for <6 months; four (22%) of 18 if used for ≥6 months (p=0·12); association between E coli with heavy periods: 61·5% of girls reporting heavy periods had E coli on cups, compared with 22·7% of those stating they did not have heavy periods (p=0·022, no numbers presented)\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nJuma et al (2017)29\n\n\nChlamydia trachomatis\n\n\nMooncup (vaginal)\nStudy end survey: cup three (2%) of 144, pads three (2%) of 201, usual practice (control) seven (5%) of 154; cup vs control p=0·20, and cup vs pads p=0·63\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nTrichomonas vaginalis\n\n\nSoftcup (cervical)\nZero cases at baseline, and cycles 1 to 3\nSample sizes not reported\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup two (1%) of 143, pads five (3%) of 200, usual practice (control) seven (5%) of 154; cup vs control p=0·12, and cup vs pads p=0·36\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\n\n\nRuby cup (vaginal)\nZero of 18 at baseline, and at 3–5 months of follow-up\nNA\nTellier et al (2012)56\n\n\nNeisseria gonorrhoea\n\n\nMooncup (vaginal)\nStudy end survey: cup one (1%) of 144, pads one (1%) of 201, usual practice (control) one (1%) of 154; cup vs control p=0·96, and cup vs pads p=0·81\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\n\n\nRuby cup (vaginal)\nZero of 18 at baseline, and at 3–5 months of follow-up\nNA\nTellier et al (2012)56\n\n\nStaphylococcus aureus\n\n\nSoftcup (cervical)\nNo significant changes in cycles 1–3 compared with baseline\nData in figure 3 of publication cannot be extracted\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nAmong menstrual cup users: four (11%) of 38 in first month of intervention, 13 (9%) of 139 after first month; p=0·83 (median follow-up 4 months, range 2–11 for this substudy); prevalence was 21 (11%) of 197 in sanitary pads group, and 16 (11%) of 153 in usual practice group\nCluster randomised trial in schools; median follow-up 11 months (range 3–15); samples from vaginal swab (self-swabbing)\nJuma et al (2017)29\n\n\n\n\nbe'Cup (vaginal)\nSilicone cup: potentially more S aureus after incubation for 8 h with shaking in a plastic bag with S aureus in one of two cups used, but not when no shaking\nIn-vitro study\nNonfoux et al (2018)73\n\n\n\n\nMe Luna (vaginal)\nThermoplastic isomer cup: no more S aureus after incubation for 8 h with shaking in plastic sac, and not when no shaking\nIn-vitro study\nNonfoux et al (2018)73\n\n\nTSST-1\n\n\nMooncup (vaginal)\n49 schoolgirls with vaginal S aureus had second swab: ten yielded S aureus, two had TSST-1, both in sanitary pad group; the cases were asymptomatic\nCluster randomised trial in schools; median follow-up 11 months (range 3–15); sample from vaginal swab (self-swabbing)\nJuma et al (2017)29\n\n\n\n\nNR\nNo TSST-1 in supernatant of S aureus cultivated for 24 h (incubated aerobically in a still growth environment) in the presence of elastic polymer menstrual cup (n=16 menstrual cups)\nIn-vitro study\nTierno et al (1989)71\n\n\n\n\nTassaway (vaginal)\n\nS aureus MN8 produced no TSST-1 when grown in the presence of Tassaway (elastomeric polymer, n=6), washed or unwashed, no shaking, incubation overnight\nIn-vitro study\nTierno at al (1994)72\n\n\n\n\nbe'Cup (vaginal)\nSilicone cup: potentially more TSST-1 production after incubation for 8 h with shaking in plastic bag with S aureus compared with control, but not when not shaken or with pieces of cup\nIn-vitro study\nNonfoux et al (2018)73\n\n\n\n\nMe Luna (vaginal)\nThermoplastic isomer cup: potentially more TSST-1 production after incubation for 8 h with shaking in plastic bag with S aureus compared with control, but not when not shaken or with pieces of cup\nIn-vitro study\nNonfoux et al (2018)73\n\n\nTSS\n\n\nMooncup (vaginal)\nZero of 192 in trial in Kenya\n“Safety monitoring components comprised routine nurse-based screening, population-based monitoring (school and community) and clinical evaluation of infection with laboratory confirmation”\nJuma et al (2017)29\n\n\n\n\nSoftcup (cervical)\nTwo case reports in the FDA database\nBoth unconfirmed cases of TSS\nNorth et al (2011)13\n\n\n\n\nDivacup (vaginal)\nOne case report: blood cultures and urine culture negative, no culture of the menstrual cup was done\nWoman had history of Hashimoto's thyroiditis and chronic menorrhagia\nMitchell et al (2015)66\n\n\n\n\nMooncup (vaginal)\nEvent February, 2012: TSS 2 days after using of first and new Mooncup resulting in 9 days of inpatient hospital stay; vaginal swab positive for S aureus\n\nHad an IUD, Mooncup was not sent for bacteriological testing\nFDA database14\n\n\n\n\nDivacup (vaginal)\nEvent February, 2015: TSS from Streptococcus resulting in 5 days of i-patient hospital stay; culture of cup isolated group A and B streptococcus\n\nWoman had used Divacup for menstrual period, which started 3 days before illness; menstrual cup was in for 18 h on admission to hospital\nFDA database14\n\n\nUTI\n\n\nRuby cup (vaginal)\nBaseline: four (13%) of 31; at follow-up (after 3–5 months) three (17%) of 18; p=0·65, McNemar test\nOne participant with a UTI at enrolment and follow-up had her cup stolen and used toilet paper in vagina as a tampon\nTellier et al (2012)56\n\n\n\n\nGynaeseal (cervical)\nOne (1%) of 73 had transient dysuria\n“The woman who developed dysuria did not seek treatment and the problem subsided within 24–48 hours”\nCattanach et al (1991)39\n\n\n\n\nSoftcup (cervical)\nUrine analysis done; detailed results not reported\n“Monthly monitoring of gynecological health via urinalysis, pelvic examination with visual evaluation of tissues, vaginal pH, and microscopic wet mount showed no adverse effects of cup use”\nNorth et al (2011)13\n\n\n\n\nSoftcup (cervical)\nEvent August, 2014: UTI confirmed by urine cultures twice after use of softcup\nMedical records were not available for evaluation\nFDA database14\n\n\nInfections overall\n\n\nTassette (vaginal)\n“The amount of bacterial contamination was greatest with the pad, next with the tampon and least with the rubber cup”\nNo data provided; study reported to make cultures from vaginal wall samples and to examine fresh and stained smears for C albicans, Trichomonas vaginalis, Haemophilus vaginalis, and for predominance of Gram-positive or Gram-negative cocci, small rods or long-rod bacilli (Doederlein bacilli)\nKarnaky et al (1962)70\n\n\n\n\nSoftcup (cervical)\nFDA database: one case report\nVaginal infection not further specified; could not be confirmed at follow-up\nNorth et al (2011)13\n\n\n\n\nButterfly cup (vaginal)\n“…none of the women sought treatment for a pelvic infection.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In India22 and Tanzania,43 the uptake of menstrual cups was significantly slower than uptake of pads (appendix p 24).22, 43 In 15 studies with relevant information, 73% (pooled estimate: n=1144, 95% CI 59–84; I2=96%) of participants reported willingness to continue use of the menstrual cup after the study (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The corresponding author had full access to all data in the study and had final responsibility to submit for publication.Results\nOf 436 unique records identified (appendix p 6), 59 were identified as relevant (figure 1), and 43 studies were included in our analysis (table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The outcomes in each of these studies were different, but leakage between products was similar in three studies and significantly less among menstrual cups for one study (figure 2).23 In studies that assessed menstrual cups that are still available, the proportion of leakage among the participants who reported use of the menstrual cup was 2–31% for a wide range of definitions, as shown in figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Some factors mentioned in association with leakage by study authors included menorrhagia,48 unusual anatomy of the uterus,53 need for a larger size of menstrual cup,5 and incorrect placement of the menstrual cup, or that it had filled to capacity.39, 53\nFigure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Safety and side-effects of the menstrual cup\n\n\n\n\nn (%) or description\nNotes\nData source\n\n\nHandling and positioning of menstrual cup\nVaginal wound\n\n\nCup not clear (Divacup or softcup)\nEvent April, 2012; vaginal wound due to use of menstrual cup, needing treatment from physician for vaginal bleeding\nComplete medical records were not available for evaluation\nFDA database14\n\n\n\n\nSoftcup (cervical)\nReported April, 2012; long-term customer of softcup product claimed vaginal scarring due to use\nMedical director did not find anything in medical records provided by customer related to vaginal health\nFDA database14\n\n\n\n\nSoftcup (cervical)\nFDA database case report: “…cup wore through the vaginal wall, damaging an artery that required surgical repair”\nEvent could not be confirmed; no medical records were available\nNorth et al (2011)13\n\n\nVaginal pain on removal\n\n\nDivacup (vaginal)\nEvent March, 2017; extreme pain on removal (first use), individual stopped using the cup\nSelf-report; no medical report available\nFDA database14\n\n\nPelvic pain\n\n\nSoftcup (cervical)\nEvent February, 2017; pain in lower pelvis and rectum and nausea about 1 h after insertion, no longer present approximately 30 min after removal\nSelf-report; no medical evaluation available; individual stopped use after trying twice (possibly vascular compression)\nFDA database14\n\n\nVaginal irritation\n\n\nGynaeseal (cervical)\nOne (1%) of 73\nSelf-report by participant\nCattanach et al (1991)39\n\n\n\n\nCervix irritation\n\n\n\nMenses cup (vaginal)\nOne (2%) of 51\nCervical smear was normal\nCheng et al (1995)41\n\n\nAllergy and rash\n\n\nNR, vaginal cup\nAllergy: one (1%) of 150; and rash: two (1%) of 150\n· ·\nKakani et al (2017)48\n\n\n\n\nSoftcup (cervical)\nFDA database: two case reports\nNR\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nEvent 2010: silicone allergy in one individual\nSurgery was needed for vaginal repair; manufacturer noted that silicone allergy is very rare\nFDA database14\n\n\nDifficulty with removal requiring professional assistance\n\n\nGynaeseal (cervical)\nOne (5%) of 22\n· ·\nGleeson et al (1993)46\n\n\n\n\nSoftcup (cervical)\nFDA database: three case reports reported by North 2011; one event in 2018\n· ·\nNorth et al (2011),13 FDA database14\n\n\n\n\nSoftcup (cervical)\nReported complaints to company 2003–08: 42 individuals underwent physician-assisted removal\nOther complaints reported to company included poor fit (n=102), leakage (n=168), messy (n=98)\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nCase report: menstrual cup lodged on cervix, difficult to remove, requiring assistance\nModerate cervical inflammation after retrieval\nDay et al (2012)63\n\n\n\n\nDivacup (vaginal)\nEvent April, 2015: one case report required an emergency room visit for removal\n· ·\nFDA database14\n\n\nReproductive tract observations with use of menstrual cup\nVulva abnormalities\n\n\nSoftcup (cervical)\nBaseline: four (1%) of 393; cycle 1: eight (2%) of 365; cycle 2: six (2%) of 326; cycle 3: five (2%) of 305\nVulva-vaginal inspection at baseline and monthly for 3 months; no p values reported\nNorth et al (2011)13\n\n\nAbnormalities of vaginal wall\n\n\nSoftcup (cervical)\nZero of 44\nVulva-vaginal inspection at baseline and monthly for 3 months\nNorth et al (2011)13\n\n\n\n\nTassette (vaginal)\nZero of 12\nVaginal inspection after 3 months\nPena et al (1962)52\n\n\n\n\nTassette (vaginal)\nZero of 50\nVaginal inspection done; timing of inspections not clear\nKarnaky et al (1962)70\n\n\nAbnormalities of cervix\n\n\nSoftcup (cervical)\nBaseline: 23 (6%) of 390; cycle 1: ten (3%) of 345; cycle 2: six (2%) of 326; cycle 3: four (1%) of 300\nInspection of cervix; no p values reported for differences\nNorth et al (2011)13\n\n\n\n\nSoftcup (cervical)\nAbnormal cervical smear test: baseline: one (<1%) of 406; cycle 1: one (<1%) of 368; cycle 2: two (1%) of 329; cycle 3: zero of 308\nAbnormal cervical smear test results were exclusion criteria at admission, and a reason for discontinuation of the study; no p values reported for differences\nNorth et al (2011)13\n\n\nCondition of vaginal and cervical epithelium\n\n\nSoftcup (cervical)\n44 women examined at baseline, 37 at 2–3 months, and 25 at 5–6 months\n“The Softcup caused no alteration or disruption in vaginal or cervical epithelium, as assessed by colposcopy and cervical cytology”\nNorth et al (2011)13\n\n\nVaginal flora and infections with use of menstrual cup\npH changes of vagina\n\n\nTassette (vaginal)\nZero of 50\nNo abnormalities, vaginal areas where menstrual cup was placed were more acid\nKarnaky et al (1962)70\n\n\n\n\nSoftcup (cervical)\nMean pH at baseline: 4·6 (n=400); cycle 1: 4·6 (n=368); cycle 2: 4·6 (n=329); cycle 3: 4·5 (n=308)\nNo p values reported\nNorth et al (2011)13\n\n\nClue cells (vaginal smear) Lactobaccilus\n\n\nSoftcup (cervical)\nNumber with clue cells: baseline n=6; cycle 1 n=6; cycle 2 n=2; cycle 3 n=4\nSample sizes and p values were not reported\nNorth et al (2011)13\n\n\nLactobaccilus\n\n\nSoftcup (cervical)\n“…before, during, and after use of the cup, vaginal Lactobacillus (normal vaginal flora) was maintained at normal levels.”\nData in figure 3 in publication cannot be extracted; no significant changes according to authors\nNorth et al (2011)13\n\n\nGardnerella vaginalis\n\n\nSoftcup (cervical)\nNo significant changes from baseline-cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nBacterial vaginosis\n\n\nSoftcup (cervical)\nNo significant changes from baseline to cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup 21 (15%) of 144; pads 40 (20%) of 202, and usual practice (control) 32 (21%) of 156; cup vs control p=0·11 and cup vs pads p=0·13; among girls enrolled for ≥9 months: cup 13 (13%) of 101, pads 29 (20%) of 143, usual practice 20 (19%) of 104; cup vs control p=0·07, and cup vs pads p=0·018\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nCandidiasis\n\n\nSoftcup (cervical)\nNumber with candidiasis: baseline n=6; cycle 1 n=6; cycle 2 n=3; cycle 3 n=6\nSample sizes not reported; according to authors, yeast decreased significantly from month 1 to 2\nNorth et al (2011)13\n\n\n\n\nRuby cup (vaginal)\nZero of 18 participants had vaginal candidiasis at follow-up (3–5 months)\nNA\nTellier et al (2012)56\n\n\n\n\nTassette (vaginal)\n\nCandida albicans decreased with the use of the cup\nNR\nKarnaky et al (1962)70\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup 11 (8%) of 143, pads 19 (10%) of 200, usual practice (control) 13 (9%) of 156; cup vs control p=0·87, and cup vs pads p=0·68\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nGroup B Streptococcus\n\n\nSoftcup (cervical)\nNo differences between baseline and cycle 1 to cycle 3\nData in figure 3 in publication cannot be extracted; no significant changes according to authors\nNorth et al (2011)13\n\n\nEnterococcus\n\n\nSoftcup (cervical)\nIncrease in Enterococcus from cycle 2 to cycle 3 (p=0·03)\n“… this increased frequency persisted for 3 months after discontinuing use of the cup, suggesting that factors or behavior other than cup use may have influenced colonization”; data in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nE coli\n\n\nSoftcup (cervical)\nNo significant changes from baseline to cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nEscherichia coli on menstrual cup\n\n\nMooncup (vaginal)\nNine (53%) of 17 if used cup for <6 months; four (22%) of 18 if used for ≥6 months (p=0·12); association between E coli with heavy periods: 61·5% of girls reporting heavy periods had E coli on cups, compared with 22·7% of those stating they did not have heavy periods (p=0·022, no numbers presented)\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nJuma et al (2017)29\n\n\nChlamydia trachomatis\n\n\nMooncup (vaginal)\nStudy end survey: cup three (2%) of 144, pads three (2%) of 201, usual practice (control) seven (5%) of 154; cup vs control p=0·20, and cup vs pads p=0·63\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nTrichomonas vaginalis\n\n\nSoftcup (cervical)\nZero cases at baseline, and cycles 1 to 3\nSample sizes not reported\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup two (1%) of 143, pads five (3%) of 200, usual practice (control) seven (5%) of 154; cup vs control p=0·12, and cup vs pads p=0·36\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\n\n\nRuby cup (vaginal)\nZero of 18 at baseline, and at 3–5 months of follow-up\nNA\nTellier et al (2012)56\n\n\nNeisseria gonorrhoea\n\n\nMooncup (vaginal)\nStudy end survey: cup one (1%) of 144, pads one (1%) of 201, usual practice (control) one (1%) of 154; cup vs control p=0·96, and cup vs pads p=0·81\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\n\n\nRuby cup (vaginal)\nZero of 18 at baseline, and at 3–5 months of follow-up\nNA\nTellier et al (2012)56\n\n\nStaphylococcus aureus\n\n\nSoftcup (cervical)\nNo significant changes in cycles 1–3 compared with baseline\nData in figure 3 of publication cannot be extracted\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nAmong menstrual cup users: four (11%) of 38 in first month of intervention, 13 (9%) of 139 after first month; p=0·83 (median follow-up 4 months, range 2–11 for this substudy); prevalence was 21 (11%) of 197 in sanitary pads group, and 16 (11%) of 153 in usual practice group\nCluster randomised trial in schools; median follow-up 11 months (range 3–15); samples from vaginal swab (self-swabbing)\nJuma et al (2017)29\n\n\n\n\nbe'Cup (vaginal)\nSilicone cup: potentially more S aureus after incubation for 8 h with shaking in a plastic bag with S aureus in one of two cups used, but not when no shaking\nIn-vitro study\nNonfoux et al (2018)73\n\n\n\n\nMe Luna (vaginal)\nThermoplastic isomer cup: no more S aureus after incubation for 8 h with shaking in plastic sac, and not when no shaking\nIn-vitro study\nNonfoux et al (2018)73\n\n\nTSST-1\n\n\nMooncup (vaginal)\n49 schoolgirls with vaginal S aureus had second swab: ten yielded S aureus, two had TSST-1, both in sanitary pad group; the cases were asymptomatic\nCluster randomised trial in schools; median follow-up 11 months (range 3–15); sample from vaginal swab (self-swabbing)\nJuma et al (2017)29\n\n\n\n\nNR\nNo TSST-1 in supernatant of S aureus cultivated for 24 h (incubated aerobically in a still growth environment) in the presence of elastic polymer menstrual cup (n=16 menstrual cups)\nIn-vitro study\nTierno et al (1989)71\n\n\n\n\nTassaway (vaginal)\n\nS aureus MN8 produced no TSST-1 when grown in the presence of Tassaway (elastomeric polymer, n=6), washed or unwashed, no shaking, incubation overnight\nIn-vitro study\nTierno at al (1994)72\n\n\n\n\nbe'Cup (vaginal)\nSilicone cup: potentially more TSST-1 production after incubation for 8 h with shaking in plastic bag with S aureus compared with control, but not when not shaken or with pieces of cup\nIn-vitro study\nNonfoux et al (2018)73\n\n\n\n\nMe Luna (vaginal)\nThermoplastic isomer cup: potentially more TSST-1 production after incubation for 8 h with shaking in plastic bag with S aureus compared with control, but not when not shaken or with pieces of cup\nIn-vitro study\nNonfoux et al (2018)73\n\n\nTSS\n\n\nMooncup (vaginal)\nZero of 192 in trial in Kenya\n“Safety monitoring components comprised routine nurse-based screening, population-based monitoring (school and community) and clinical evaluation of infection with laboratory confirmation”\nJuma et al (2017)29\n\n\n\n\nSoftcup (cervical)\nTwo case reports in the FDA database\nBoth unconfirmed cases of TSS\nNorth et al (2011)13\n\n\n\n\nDivacup (vaginal)\nOne case report: blood cultures and urine culture negative, no culture of the menstrual cup was done\nWoman had history of Hashimoto's thyroiditis and chronic menorrhagia\nMitchell et al (2015)66\n\n\n\n\nMooncup (vaginal)\nEvent February, 2012: TSS 2 days after using of first and new Mooncup resulting in 9 days of inpatient hospital stay; vaginal swab positive for S aureus\n\nHad an IUD, Mooncup was not sent for bacteriological testing\nFDA database14\n\n\n\n\nDivacup (vaginal)\nEvent February, 2015: TSS from Streptococcus resulting in 5 days of i-patient hospital stay; culture of cup isolated group A and B streptococcus\n\nWoman had used Divacup for menstrual period, which started 3 days before illness; menstrual cup was in for 18 h on admission to hospital\nFDA database14\n\n\nUTI\n\n\nRuby cup (vaginal)\nBaseline: four (13%) of 31; at follow-up (after 3–5 months) three (17%) of 18; p=0·65, McNemar test\nOne participant with a UTI at enrolment and follow-up had her cup stolen and used toilet paper in vagina as a tampon\nTellier et al (2012)56\n\n\n\n\nGynaeseal (cervical)\nOne (1%) of 73 had transient dysuria\n“The woman who developed dysuria did not seek treatment and the problem subsided within 24–48 hours”\nCattanach et al (1991)39\n\n\n\n\nSoftcup (cervical)\nUrine analysis done; detailed results not reported\n“Monthly monitoring of gynecological health via urinalysis, pelvic examination with visual evaluation of tissues, vaginal pH, and microscopic wet mount showed no adverse effects of cup use”\nNorth et al (2011)13\n\n\n\n\nSoftcup (cervical)\nEvent August, 2014: UTI confirmed by urine cultures twice after use of softcup\nMedical records were not available for evaluation\nFDA database14\n\n\nInfections overall\n\n\nTassette (vaginal)\n“The amount of bacterial contamination was greatest with the pad, next with the tampon and least with the rubber cup”\nNo data provided; study reported to make cultures from vaginal wall samples and to examine fresh and stained smears for C albicans, Trichomonas vaginalis, Haemophilus vaginalis, and for predominance of Gram-positive or Gram-negative cocci, small rods or long-rod bacilli (Doederlein bacilli)\nKarnaky et al (1962)70\n\n\n\n\nSoftcup (cervical)\nFDA database: one case report\nVaginal infection not further specified; could not be confirmed at follow-up\nNorth et al (2011)13\n\n\n\n\nButterfly cup (vaginal)\n“…none of the women sought treatment for a pelvic infection.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In India22 and Tanzania,43 the uptake of menstrual cups was significantly slower than uptake of pads (appendix p 24).22, 43 In 15 studies with relevant information, 73% (pooled estimate: n=1144, 95% CI 59–84; I2=96%) of participants reported willingness to continue use of the menstrual cup after the study (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The corresponding author had full access to all data in the study and had final responsibility to submit for publication.Results\nOf 436 unique records identified (appendix p 6), 59 were identified as relevant (figure 1), and 43 studies were included in our analysis (table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The outcomes in each of these studies were different, but leakage between products was similar in three studies and significantly less among menstrual cups for one study (figure 2).23 In studies that assessed menstrual cups that are still available, the proportion of leakage among the participants who reported use of the menstrual cup was 2–31% for a wide range of definitions, as shown in figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Some factors mentioned in association with leakage by study authors included menorrhagia,48 unusual anatomy of the uterus,53 need for a larger size of menstrual cup,5 and incorrect placement of the menstrual cup, or that it had filled to capacity.39, 53\nFigure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Safety and side-effects of the menstrual cup\n\n\n\n\nn (%) or description\nNotes\nData source\n\n\nHandling and positioning of menstrual cup\nVaginal wound\n\n\nCup not clear (Divacup or softcup)\nEvent April, 2012; vaginal wound due to use of menstrual cup, needing treatment from physician for vaginal bleeding\nComplete medical records were not available for evaluation\nFDA database14\n\n\n\n\nSoftcup (cervical)\nReported April, 2012; long-term customer of softcup product claimed vaginal scarring due to use\nMedical director did not find anything in medical records provided by customer related to vaginal health\nFDA database14\n\n\n\n\nSoftcup (cervical)\nFDA database case report: “…cup wore through the vaginal wall, damaging an artery that required surgical repair”\nEvent could not be confirmed; no medical records were available\nNorth et al (2011)13\n\n\nVaginal pain on removal\n\n\nDivacup (vaginal)\nEvent March, 2017; extreme pain on removal (first use), individual stopped using the cup\nSelf-report; no medical report available\nFDA database14\n\n\nPelvic pain\n\n\nSoftcup (cervical)\nEvent February, 2017; pain in lower pelvis and rectum and nausea about 1 h after insertion, no longer present approximately 30 min after removal\nSelf-report; no medical evaluation available; individual stopped use after trying twice (possibly vascular compression)\nFDA database14\n\n\nVaginal irritation\n\n\nGynaeseal (cervical)\nOne (1%) of 73\nSelf-report by participant\nCattanach et al (1991)39\n\n\n\n\nCervix irritation\n\n\n\nMenses cup (vaginal)\nOne (2%) of 51\nCervical smear was normal\nCheng et al (1995)41\n\n\nAllergy and rash\n\n\nNR, vaginal cup\nAllergy: one (1%) of 150; and rash: two (1%) of 150\n· ·\nKakani et al (2017)48\n\n\n\n\nSoftcup (cervical)\nFDA database: two case reports\nNR\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nEvent 2010: silicone allergy in one individual\nSurgery was needed for vaginal repair; manufacturer noted that silicone allergy is very rare\nFDA database14\n\n\nDifficulty with removal requiring professional assistance\n\n\nGynaeseal (cervical)\nOne (5%) of 22\n· ·\nGleeson et al (1993)46\n\n\n\n\nSoftcup (cervical)\nFDA database: three case reports reported by North 2011; one event in 2018\n· ·\nNorth et al (2011),13 FDA database14\n\n\n\n\nSoftcup (cervical)\nReported complaints to company 2003–08: 42 individuals underwent physician-assisted removal\nOther complaints reported to company included poor fit (n=102), leakage (n=168), messy (n=98)\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nCase report: menstrual cup lodged on cervix, difficult to remove, requiring assistance\nModerate cervical inflammation after retrieval\nDay et al (2012)63\n\n\n\n\nDivacup (vaginal)\nEvent April, 2015: one case report required an emergency room visit for removal\n· ·\nFDA database14\n\n\nReproductive tract observations with use of menstrual cup\nVulva abnormalities\n\n\nSoftcup (cervical)\nBaseline: four (1%) of 393; cycle 1: eight (2%) of 365; cycle 2: six (2%) of 326; cycle 3: five (2%) of 305\nVulva-vaginal inspection at baseline and monthly for 3 months; no p values reported\nNorth et al (2011)13\n\n\nAbnormalities of vaginal wall\n\n\nSoftcup (cervical)\nZero of 44\nVulva-vaginal inspection at baseline and monthly for 3 months\nNorth et al (2011)13\n\n\n\n\nTassette (vaginal)\nZero of 12\nVaginal inspection after 3 months\nPena et al (1962)52\n\n\n\n\nTassette (vaginal)\nZero of 50\nVaginal inspection done; timing of inspections not clear\nKarnaky et al (1962)70\n\n\nAbnormalities of cervix\n\n\nSoftcup (cervical)\nBaseline: 23 (6%) of 390; cycle 1: ten (3%) of 345; cycle 2: six (2%) of 326; cycle 3: four (1%) of 300\nInspection of cervix; no p values reported for differences\nNorth et al (2011)13\n\n\n\n\nSoftcup (cervical)\nAbnormal cervical smear test: baseline: one (<1%) of 406; cycle 1: one (<1%) of 368; cycle 2: two (1%) of 329; cycle 3: zero of 308\nAbnormal cervical smear test results were exclusion criteria at admission, and a reason for discontinuation of the study; no p values reported for differences\nNorth et al (2011)13\n\n\nCondition of vaginal and cervical epithelium\n\n\nSoftcup (cervical)\n44 women examined at baseline, 37 at 2–3 months, and 25 at 5–6 months\n“The Softcup caused no alteration or disruption in vaginal or cervical epithelium, as assessed by colposcopy and cervical cytology”\nNorth et al (2011)13\n\n\nVaginal flora and infections with use of menstrual cup\npH changes of vagina\n\n\nTassette (vaginal)\nZero of 50\nNo abnormalities, vaginal areas where menstrual cup was placed were more acid\nKarnaky et al (1962)70\n\n\n\n\nSoftcup (cervical)\nMean pH at baseline: 4·6 (n=400); cycle 1: 4·6 (n=368); cycle 2: 4·6 (n=329); cycle 3: 4·5 (n=308)\nNo p values reported\nNorth et al (2011)13\n\n\nClue cells (vaginal smear) Lactobaccilus\n\n\nSoftcup (cervical)\nNumber with clue cells: baseline n=6; cycle 1 n=6; cycle 2 n=2; cycle 3 n=4\nSample sizes and p values were not reported\nNorth et al (2011)13\n\n\nLactobaccilus\n\n\nSoftcup (cervical)\n“…before, during, and after use of the cup, vaginal Lactobacillus (normal vaginal flora) was maintained at normal levels.”\nData in figure 3 in publication cannot be extracted; no significant changes according to authors\nNorth et al (2011)13\n\n\nGardnerella vaginalis\n\n\nSoftcup (cervical)\nNo significant changes from baseline-cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nBacterial vaginosis\n\n\nSoftcup (cervical)\nNo significant changes from baseline to cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup 21 (15%) of 144; pads 40 (20%) of 202, and usual practice (control) 32 (21%) of 156; cup vs control p=0·11 and cup vs pads p=0·13; among girls enrolled for ≥9 months: cup 13 (13%) of 101, pads 29 (20%) of 143, usual practice 20 (19%) of 104; cup vs control p=0·07, and cup vs pads p=0·018\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nCandidiasis\n\n\nSoftcup (cervical)\nNumber with candidiasis: baseline n=6; cycle 1 n=6; cycle 2 n=3; cycle 3 n=6\nSample sizes not reported; according to authors, yeast decreased significantly from month 1 to 2\nNorth et al (2011)13\n\n\n\n\nRuby cup (vaginal)\nZero of 18 participants had vaginal candidiasis at follow-up (3–5 months)\nNA\nTellier et al (2012)56\n\n\n\n\nTassette (vaginal)\n\nCandida albicans decreased with the use of the cup\nNR\nKarnaky et al (1962)70\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup 11 (8%) of 143, pads 19 (10%) of 200, usual practice (control) 13 (9%) of 156; cup vs control p=0·87, and cup vs pads p=0·68\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nGroup B Streptococcus\n\n\nSoftcup (cervical)\nNo differences between baseline and cycle 1 to cycle 3\nData in figure 3 in publication cannot be extracted; no significant changes according to authors\nNorth et al (2011)13\n\n\nEnterococcus\n\n\nSoftcup (cervical)\nIncrease in Enterococcus from cycle 2 to cycle 3 (p=0·03)\n“… this increased frequency persisted for 3 months after discontinuing use of the cup, suggesting that factors or behavior other than cup use may have influenced colonization”; data in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nE coli\n\n\nSoftcup (cervical)\nNo significant changes from baseline to cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nEscherichia coli on menstrual cup\n\n\nMooncup (vaginal)\nNine (53%) of 17 if used cup for <6 months; four (22%) of 18 if used for ≥6 months (p=0·12); association between E coli with heavy periods: 61·5% of girls reporting heavy periods had E coli on cups, compared with 22·7% of those stating they did not have heavy periods (p=0·022, no numbers presented)\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nJuma et al (2017)29\n\n\nChlamydia trachomatis\n\n\nMooncup (vaginal)\nStudy end survey: cup three (2%) of 144, pads three (2%) of 201, usual practice (control) seven (5%) of 154; cup vs control p=0·20, and cup vs pads p=0·63\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nTrichomonas vaginalis\n\n\nSoftcup (cervical)\nZero cases at baseline, and cycles 1 to 3\nSample sizes not reported\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup two (1%) of 143, pads five (3%) of 200, usual practice (control) seven (5%) of 154; cup vs control p=0·12, and cup vs pads p=0·36\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\n\n\nRuby cup (vaginal)\nZero of 18 at baseline, and at 3–5 months of follow-up\nNA\nTellier et al (2012)56\n\n\nNeisseria gonorrhoea\n\n\nMooncup (vaginal)\nStudy end survey: cup one (1%) of 144, pads one (1%) of 201, usual practice (control) one (1%) of 154; cup vs control p=0·96, and cup vs pads p=0·81\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\n\n\nRuby cup (vaginal)\nZero of 18 at baseline, and at 3–5 months of follow-up\nNA\nTellier et al (2012)56\n\n\nStaphylococcus aureus\n\n\nSoftcup (cervical)\nNo significant changes in cycles 1–3 compared with baseline\nData in figure 3 of publication cannot be extracted\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nAmong menstrual cup users: four (11%) of 38 in first month of intervention, 13 (9%) of 139 after first month; p=0·83 (median follow-up 4 months, range 2–11 for this substudy); prevalence was 21 (11%) of 197 in sanitary pads group, and 16 (11%) of 153 in usual practice group\nCluster randomised trial in schools; median follow-up 11 months (range 3–15); samples from vaginal swab (self-swabbing)\nJuma et al (2017)29\n\n\n\n\nbe'Cup (vaginal)\nSilicone cup: potentially more S aureus after incubation for 8 h with shaking in a plastic bag with S aureus in one of two cups used, but not when no shaking\nIn-vitro study\nNonfoux et al (2018)73\n\n\n\n\nMe Luna (vaginal)\nThermoplastic isomer cup: no more S aureus after incubation for 8 h with shaking in plastic sac, and not when no shaking\nIn-vitro study\nNonfoux et al (2018)73\n\n\nTSST-1\n\n\nMooncup (vaginal)\n49 schoolgirls with vaginal S aureus had second swab: ten yielded S aureus, two had TSST-1, both in sanitary pad group; the cases were asymptomatic\nCluster randomised trial in schools; median follow-up 11 months (range 3–15); sample from vaginal swab (self-swabbing)\nJuma et al (2017)29\n\n\n\n\nNR\nNo TSST-1 in supernatant of S aureus cultivated for 24 h (incubated aerobically in a still growth environment) in the presence of elastic polymer menstrual cup (n=16 menstrual cups)\nIn-vitro study\nTierno et al (1989)71\n\n\n\n\nTassaway (vaginal)\n\nS aureus MN8 produced no TSST-1 when grown in the presence of Tassaway (elastomeric polymer, n=6), washed or unwashed, no shaking, incubation overnight\nIn-vitro study\nTierno at al (1994)72\n\n\n\n\nbe'Cup (vaginal)\nSilicone cup: potentially more TSST-1 production after incubation for 8 h with shaking in plastic bag with S aureus compared with control, but not when not shaken or with pieces of cup\nIn-vitro study\nNonfoux et al (2018)73\n\n\n\n\nMe Luna (vaginal)\nThermoplastic isomer cup: potentially more TSST-1 production after incubation for 8 h with shaking in plastic bag with S aureus compared with control, but not when not shaken or with pieces of cup\nIn-vitro study\nNonfoux et al (2018)73\n\n\nTSS\n\n\nMooncup (vaginal)\nZero of 192 in trial in Kenya\n“Safety monitoring components comprised routine nurse-based screening, population-based monitoring (school and community) and clinical evaluation of infection with laboratory confirmation”\nJuma et al (2017)29\n\n\n\n\nSoftcup (cervical)\nTwo case reports in the FDA database\nBoth unconfirmed cases of TSS\nNorth et al (2011)13\n\n\n\n\nDivacup (vaginal)\nOne case report: blood cultures and urine culture negative, no culture of the menstrual cup was done\nWoman had history of Hashimoto's thyroiditis and chronic menorrhagia\nMitchell et al (2015)66\n\n\n\n\nMooncup (vaginal)\nEvent February, 2012: TSS 2 days after using of first and new Mooncup resulting in 9 days of inpatient hospital stay; vaginal swab positive for S aureus\n\nHad an IUD, Mooncup was not sent for bacteriological testing\nFDA database14\n\n\n\n\nDivacup (vaginal)\nEvent February, 2015: TSS from Streptococcus resulting in 5 days of i-patient hospital stay; culture of cup isolated group A and B streptococcus\n\nWoman had used Divacup for menstrual period, which started 3 days before illness; menstrual cup was in for 18 h on admission to hospital\nFDA database14\n\n\nUTI\n\n\nRuby cup (vaginal)\nBaseline: four (13%) of 31; at follow-up (after 3–5 months) three (17%) of 18; p=0·65, McNemar test\nOne participant with a UTI at enrolment and follow-up had her cup stolen and used toilet paper in vagina as a tampon\nTellier et al (2012)56\n\n\n\n\nGynaeseal (cervical)\nOne (1%) of 73 had transient dysuria\n“The woman who developed dysuria did not seek treatment and the problem subsided within 24–48 hours”\nCattanach et al (1991)39\n\n\n\n\nSoftcup (cervical)\nUrine analysis done; detailed results not reported\n“Monthly monitoring of gynecological health via urinalysis, pelvic examination with visual evaluation of tissues, vaginal pH, and microscopic wet mount showed no adverse effects of cup use”\nNorth et al (2011)13\n\n\n\n\nSoftcup (cervical)\nEvent August, 2014: UTI confirmed by urine cultures twice after use of softcup\nMedical records were not available for evaluation\nFDA database14\n\n\nInfections overall\n\n\nTassette (vaginal)\n“The amount of bacterial contamination was greatest with the pad, next with the tampon and least with the rubber cup”\nNo data provided; study reported to make cultures from vaginal wall samples and to examine fresh and stained smears for C albicans, Trichomonas vaginalis, Haemophilus vaginalis, and for predominance of Gram-positive or Gram-negative cocci, small rods or long-rod bacilli (Doederlein bacilli)\nKarnaky et al (1962)70\n\n\n\n\nSoftcup (cervical)\nFDA database: one case report\nVaginal infection not further specified; could not be confirmed at follow-up\nNorth et al (2011)13\n\n\n\n\nButterfly cup (vaginal)\n“…none of the women sought treatment for a pelvic infection.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In India22 and Tanzania,43 the uptake of menstrual cups was significantly slower than uptake of pads (appendix p 24).22, 43 In 15 studies with relevant information, 73% (pooled estimate: n=1144, 95% CI 59–84; I2=96%) of participants reported willingness to continue use of the menstrual cup after the study (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Results\nOf 436 unique records identified (appendix p 6), 59 were identified as relevant (figure 1), and 43 studies were included in our analysis (table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The outcomes in each of these studies were different, but leakage between products was similar in three studies and significantly less among menstrual cups for one study (figure 2).23 In studies that assessed menstrual cups that are still available, the proportion of leakage among the participants who reported use of the menstrual cup was 2–31% for a wide range of definitions, as shown in figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Some factors mentioned in association with leakage by study authors included menorrhagia,48 unusual anatomy of the uterus,53 need for a larger size of menstrual cup,5 and incorrect placement of the menstrual cup, or that it had filled to capacity.39, 53\nFigure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Safety and side-effects of the menstrual cup\n\n\n\n\nn (%) or description\nNotes\nData source\n\n\nHandling and positioning of menstrual cup\nVaginal wound\n\n\nCup not clear (Divacup or softcup)\nEvent April, 2012; vaginal wound due to use of menstrual cup, needing treatment from physician for vaginal bleeding\nComplete medical records were not available for evaluation\nFDA database14\n\n\n\n\nSoftcup (cervical)\nReported April, 2012; long-term customer of softcup product claimed vaginal scarring due to use\nMedical director did not find anything in medical records provided by customer related to vaginal health\nFDA database14\n\n\n\n\nSoftcup (cervical)\nFDA database case report: “…cup wore through the vaginal wall, damaging an artery that required surgical repair”\nEvent could not be confirmed; no medical records were available\nNorth et al (2011)13\n\n\nVaginal pain on removal\n\n\nDivacup (vaginal)\nEvent March, 2017; extreme pain on removal (first use), individual stopped using the cup\nSelf-report; no medical report available\nFDA database14\n\n\nPelvic pain\n\n\nSoftcup (cervical)\nEvent February, 2017; pain in lower pelvis and rectum and nausea about 1 h after insertion, no longer present approximately 30 min after removal\nSelf-report; no medical evaluation available; individual stopped use after trying twice (possibly vascular compression)\nFDA database14\n\n\nVaginal irritation\n\n\nGynaeseal (cervical)\nOne (1%) of 73\nSelf-report by participant\nCattanach et al (1991)39\n\n\n\n\nCervix irritation\n\n\n\nMenses cup (vaginal)\nOne (2%) of 51\nCervical smear was normal\nCheng et al (1995)41\n\n\nAllergy and rash\n\n\nNR, vaginal cup\nAllergy: one (1%) of 150; and rash: two (1%) of 150\n· ·\nKakani et al (2017)48\n\n\n\n\nSoftcup (cervical)\nFDA database: two case reports\nNR\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nEvent 2010: silicone allergy in one individual\nSurgery was needed for vaginal repair; manufacturer noted that silicone allergy is very rare\nFDA database14\n\n\nDifficulty with removal requiring professional assistance\n\n\nGynaeseal (cervical)\nOne (5%) of 22\n· ·\nGleeson et al (1993)46\n\n\n\n\nSoftcup (cervical)\nFDA database: three case reports reported by North 2011; one event in 2018\n· ·\nNorth et al (2011),13 FDA database14\n\n\n\n\nSoftcup (cervical)\nReported complaints to company 2003–08: 42 individuals underwent physician-assisted removal\nOther complaints reported to company included poor fit (n=102), leakage (n=168), messy (n=98)\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nCase report: menstrual cup lodged on cervix, difficult to remove, requiring assistance\nModerate cervical inflammation after retrieval\nDay et al (2012)63\n\n\n\n\nDivacup (vaginal)\nEvent April, 2015: one case report required an emergency room visit for removal\n· ·\nFDA database14\n\n\nReproductive tract observations with use of menstrual cup\nVulva abnormalities\n\n\nSoftcup (cervical)\nBaseline: four (1%) of 393; cycle 1: eight (2%) of 365; cycle 2: six (2%) of 326; cycle 3: five (2%) of 305\nVulva-vaginal inspection at baseline and monthly for 3 months; no p values reported\nNorth et al (2011)13\n\n\nAbnormalities of vaginal wall\n\n\nSoftcup (cervical)\nZero of 44\nVulva-vaginal inspection at baseline and monthly for 3 months\nNorth et al (2011)13\n\n\n\n\nTassette (vaginal)\nZero of 12\nVaginal inspection after 3 months\nPena et al (1962)52\n\n\n\n\nTassette (vaginal)\nZero of 50\nVaginal inspection done; timing of inspections not clear\nKarnaky et al (1962)70\n\n\nAbnormalities of cervix\n\n\nSoftcup (cervical)\nBaseline: 23 (6%) of 390; cycle 1: ten (3%) of 345; cycle 2: six (2%) of 326; cycle 3: four (1%) of 300\nInspection of cervix; no p values reported for differences\nNorth et al (2011)13\n\n\n\n\nSoftcup (cervical)\nAbnormal cervical smear test: baseline: one (<1%) of 406; cycle 1: one (<1%) of 368; cycle 2: two (1%) of 329; cycle 3: zero of 308\nAbnormal cervical smear test results were exclusion criteria at admission, and a reason for discontinuation of the study; no p values reported for differences\nNorth et al (2011)13\n\n\nCondition of vaginal and cervical epithelium\n\n\nSoftcup (cervical)\n44 women examined at baseline, 37 at 2–3 months, and 25 at 5–6 months\n“The Softcup caused no alteration or disruption in vaginal or cervical epithelium, as assessed by colposcopy and cervical cytology”\nNorth et al (2011)13\n\n\nVaginal flora and infections with use of menstrual cup\npH changes of vagina\n\n\nTassette (vaginal)\nZero of 50\nNo abnormalities, vaginal areas where menstrual cup was placed were more acid\nKarnaky et al (1962)70\n\n\n\n\nSoftcup (cervical)\nMean pH at baseline: 4·6 (n=400); cycle 1: 4·6 (n=368); cycle 2: 4·6 (n=329); cycle 3: 4·5 (n=308)\nNo p values reported\nNorth et al (2011)13\n\n\nClue cells (vaginal smear) Lactobaccilus\n\n\nSoftcup (cervical)\nNumber with clue cells: baseline n=6; cycle 1 n=6; cycle 2 n=2; cycle 3 n=4\nSample sizes and p values were not reported\nNorth et al (2011)13\n\n\nLactobaccilus\n\n\nSoftcup (cervical)\n“…before, during, and after use of the cup, vaginal Lactobacillus (normal vaginal flora) was maintained at normal levels.”\nData in figure 3 in publication cannot be extracted; no significant changes according to authors\nNorth et al (2011)13\n\n\nGardnerella vaginalis\n\n\nSoftcup (cervical)\nNo significant changes from baseline-cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nBacterial vaginosis\n\n\nSoftcup (cervical)\nNo significant changes from baseline to cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup 21 (15%) of 144; pads 40 (20%) of 202, and usual practice (control) 32 (21%) of 156; cup vs control p=0·11 and cup vs pads p=0·13; among girls enrolled for ≥9 months: cup 13 (13%) of 101, pads 29 (20%) of 143, usual practice 20 (19%) of 104; cup vs control p=0·07, and cup vs pads p=0·018\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nCandidiasis\n\n\nSoftcup (cervical)\nNumber with candidiasis: baseline n=6; cycle 1 n=6; cycle 2 n=3; cycle 3 n=6\nSample sizes not reported; according to authors, yeast decreased significantly from month 1 to 2\nNorth et al (2011)13\n\n\n\n\nRuby cup (vaginal)\nZero of 18 participants had vaginal candidiasis at follow-up (3–5 months)\nNA\nTellier et al (2012)56\n\n\n\n\nTassette (vaginal)\n\nCandida albicans decreased with the use of the cup\nNR\nKarnaky et al (1962)70\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup 11 (8%) of 143, pads 19 (10%) of 200, usual practice (control) 13 (9%) of 156; cup vs control p=0·87, and cup vs pads p=0·68\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nGroup B Streptococcus\n\n\nSoftcup (cervical)\nNo differences between baseline and cycle 1 to cycle 3\nData in figure 3 in publication cannot be extracted; no significant changes according to authors\nNorth et al (2011)13\n\n\nEnterococcus\n\n\nSoftcup (cervical)\nIncrease in Enterococcus from cycle 2 to cycle 3 (p=0·03)\n“… this increased frequency persisted for 3 months after discontinuing use of the cup, suggesting that factors or behavior other than cup use may have influenced colonization”; data in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nE coli\n\n\nSoftcup (cervical)\nNo significant changes from baseline to cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nEscherichia coli on menstrual cup\n\n\nMooncup (vaginal)\nNine (53%) of 17 if used cup for <6 months; four (22%) of 18 if used for ≥6 months (p=0·12); association between E coli with heavy periods: 61·5% of girls reporting heavy periods had E coli on cups, compared with 22·7% of those stating they did not have heavy periods (p=0·022, no numbers presented)\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nJuma et al (2017)29\n\n\nChlamydia trachomatis\n\n\nMooncup (vaginal)\nStudy end survey: cup three (2%) of 144, pads three (2%) of 201, usual practice (control) seven (5%) of 154; cup vs control p=0·20, and cup vs pads p=0·63\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nTrichomonas vaginalis\n\n\nSoftcup (cervical)\nZero cases at baseline, and cycles 1 to 3\nSample sizes not reported\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup two (1%) of 143, pads five (3%) of 200, usual practice (control) seven (5%) of 154; cup vs control p=0·12, and cup vs pads p=0·36\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\n\n\nRuby cup (vaginal)\nZero of 18 at baseline, and at 3–5 months of follow-up\nNA\nTellier et al (2012)56\n\n\nNeisseria gonorrhoea\n\n\nMooncup (vaginal)\nStudy end survey: cup one (1%) of 144, pads one (1%) of 201, usual practice (control) one (1%) of 154; cup vs control p=0·96, and cup vs pads p=0·81\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\n\n\nRuby cup (vaginal)\nZero of 18 at baseline, and at 3–5 months of follow-up\nNA\nTellier et al (2012)56\n\n\nStaphylococcus aureus\n\n\nSoftcup (cervical)\nNo significant changes in cycles 1–3 compared with baseline\nData in figure 3 of publication cannot be extracted\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nAmong menstrual cup users: four (11%) of 38 in first month of intervention, 13 (9%) of 139 after first month; p=0·83 (median follow-up 4 months, range 2–11 for this substudy); prevalence was 21 (11%) of 197 in sanitary pads group, and 16 (11%) of 153 in usual practice group\nCluster randomised trial in schools; median follow-up 11 months (range 3–15); samples from vaginal swab (self-swabbing)\nJuma et al (2017)29\n\n\n\n\nbe'Cup (vaginal)\nSilicone cup: potentially more S aureus after incubation for 8 h with shaking in a plastic bag with S aureus in one of two cups used, but not when no shaking\nIn-vitro study\nNonfoux et al (2018)73\n\n\n\n\nMe Luna (vaginal)\nThermoplastic isomer cup: no more S aureus after incubation for 8 h with shaking in plastic sac, and not when no shaking\nIn-vitro study\nNonfoux et al (2018)73\n\n\nTSST-1\n\n\nMooncup (vaginal)\n49 schoolgirls with vaginal S aureus had second swab: ten yielded S aureus, two had TSST-1, both in sanitary pad group; the cases were asymptomatic\nCluster randomised trial in schools; median follow-up 11 months (range 3–15); sample from vaginal swab (self-swabbing)\nJuma et al (2017)29\n\n\n\n\nNR\nNo TSST-1 in supernatant of S aureus cultivated for 24 h (incubated aerobically in a still growth environment) in the presence of elastic polymer menstrual cup (n=16 menstrual cups)\nIn-vitro study\nTierno et al (1989)71\n\n\n\n\nTassaway (vaginal)\n\nS aureus MN8 produced no TSST-1 when grown in the presence of Tassaway (elastomeric polymer, n=6), washed or unwashed, no shaking, incubation overnight\nIn-vitro study\nTierno at al (1994)72\n\n\n\n\nbe'Cup (vaginal)\nSilicone cup: potentially more TSST-1 production after incubation for 8 h with shaking in plastic bag with S aureus compared with control, but not when not shaken or with pieces of cup\nIn-vitro study\nNonfoux et al (2018)73\n\n\n\n\nMe Luna (vaginal)\nThermoplastic isomer cup: potentially more TSST-1 production after incubation for 8 h with shaking in plastic bag with S aureus compared with control, but not when not shaken or with pieces of cup\nIn-vitro study\nNonfoux et al (2018)73\n\n\nTSS\n\n\nMooncup (vaginal)\nZero of 192 in trial in Kenya\n“Safety monitoring components comprised routine nurse-based screening, population-based monitoring (school and community) and clinical evaluation of infection with laboratory confirmation”\nJuma et al (2017)29\n\n\n\n\nSoftcup (cervical)\nTwo case reports in the FDA database\nBoth unconfirmed cases of TSS\nNorth et al (2011)13\n\n\n\n\nDivacup (vaginal)\nOne case report: blood cultures and urine culture negative, no culture of the menstrual cup was done\nWoman had history of Hashimoto's thyroiditis and chronic menorrhagia\nMitchell et al (2015)66\n\n\n\n\nMooncup (vaginal)\nEvent February, 2012: TSS 2 days after using of first and new Mooncup resulting in 9 days of inpatient hospital stay; vaginal swab positive for S aureus\n\nHad an IUD, Mooncup was not sent for bacteriological testing\nFDA database14\n\n\n\n\nDivacup (vaginal)\nEvent February, 2015: TSS from Streptococcus resulting in 5 days of i-patient hospital stay; culture of cup isolated group A and B streptococcus\n\nWoman had used Divacup for menstrual period, which started 3 days before illness; menstrual cup was in for 18 h on admission to hospital\nFDA database14\n\n\nUTI\n\n\nRuby cup (vaginal)\nBaseline: four (13%) of 31; at follow-up (after 3–5 months) three (17%) of 18; p=0·65, McNemar test\nOne participant with a UTI at enrolment and follow-up had her cup stolen and used toilet paper in vagina as a tampon\nTellier et al (2012)56\n\n\n\n\nGynaeseal (cervical)\nOne (1%) of 73 had transient dysuria\n“The woman who developed dysuria did not seek treatment and the problem subsided within 24–48 hours”\nCattanach et al (1991)39\n\n\n\n\nSoftcup (cervical)\nUrine analysis done; detailed results not reported\n“Monthly monitoring of gynecological health via urinalysis, pelvic examination with visual evaluation of tissues, vaginal pH, and microscopic wet mount showed no adverse effects of cup use”\nNorth et al (2011)13\n\n\n\n\nSoftcup (cervical)\nEvent August, 2014: UTI confirmed by urine cultures twice after use of softcup\nMedical records were not available for evaluation\nFDA database14\n\n\nInfections overall\n\n\nTassette (vaginal)\n“The amount of bacterial contamination was greatest with the pad, next with the tampon and least with the rubber cup”\nNo data provided; study reported to make cultures from vaginal wall samples and to examine fresh and stained smears for C albicans, Trichomonas vaginalis, Haemophilus vaginalis, and for predominance of Gram-positive or Gram-negative cocci, small rods or long-rod bacilli (Doederlein bacilli)\nKarnaky et al (1962)70\n\n\n\n\nSoftcup (cervical)\nFDA database: one case report\nVaginal infection not further specified; could not be confirmed at follow-up\nNorth et al (2011)13\n\n\n\n\nButterfly cup (vaginal)\n“…none of the women sought treatment for a pelvic infection.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In India22 and Tanzania,43 the uptake of menstrual cups was significantly slower than uptake of pads (appendix p 24).22, 43 In 15 studies with relevant information, 73% (pooled estimate: n=1144, 95% CI 59–84; I2=96%) of participants reported willingness to continue use of the menstrual cup after the study (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Of 436 unique records identified (appendix p 6), 59 were identified as relevant (figure 1), and 43 studies were included in our analysis (table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The outcomes in each of these studies were different, but leakage between products was similar in three studies and significantly less among menstrual cups for one study (figure 2).23 In studies that assessed menstrual cups that are still available, the proportion of leakage among the participants who reported use of the menstrual cup was 2–31% for a wide range of definitions, as shown in figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Safety and side-effects of the menstrual cup\n\n\n\n\nn (%) or description\nNotes\nData source\n\n\nHandling and positioning of menstrual cup\nVaginal wound\n\n\nCup not clear (Divacup or softcup)\nEvent April, 2012; vaginal wound due to use of menstrual cup, needing treatment from physician for vaginal bleeding\nComplete medical records were not available for evaluation\nFDA database14\n\n\n\n\nSoftcup (cervical)\nReported April, 2012; long-term customer of softcup product claimed vaginal scarring due to use\nMedical director did not find anything in medical records provided by customer related to vaginal health\nFDA database14\n\n\n\n\nSoftcup (cervical)\nFDA database case report: “…cup wore through the vaginal wall, damaging an artery that required surgical repair”\nEvent could not be confirmed; no medical records were available\nNorth et al (2011)13\n\n\nVaginal pain on removal\n\n\nDivacup (vaginal)\nEvent March, 2017; extreme pain on removal (first use), individual stopped using the cup\nSelf-report; no medical report available\nFDA database14\n\n\nPelvic pain\n\n\nSoftcup (cervical)\nEvent February, 2017; pain in lower pelvis and rectum and nausea about 1 h after insertion, no longer present approximately 30 min after removal\nSelf-report; no medical evaluation available; individual stopped use after trying twice (possibly vascular compression)\nFDA database14\n\n\nVaginal irritation\n\n\nGynaeseal (cervical)\nOne (1%) of 73\nSelf-report by participant\nCattanach et al (1991)39\n\n\n\n\nCervix irritation\n\n\n\nMenses cup (vaginal)\nOne (2%) of 51\nCervical smear was normal\nCheng et al (1995)41\n\n\nAllergy and rash\n\n\nNR, vaginal cup\nAllergy: one (1%) of 150; and rash: two (1%) of 150\n· ·\nKakani et al (2017)48\n\n\n\n\nSoftcup (cervical)\nFDA database: two case reports\nNR\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nEvent 2010: silicone allergy in one individual\nSurgery was needed for vaginal repair; manufacturer noted that silicone allergy is very rare\nFDA database14\n\n\nDifficulty with removal requiring professional assistance\n\n\nGynaeseal (cervical)\nOne (5%) of 22\n· ·\nGleeson et al (1993)46\n\n\n\n\nSoftcup (cervical)\nFDA database: three case reports reported by North 2011; one event in 2018\n· ·\nNorth et al (2011),13 FDA database14\n\n\n\n\nSoftcup (cervical)\nReported complaints to company 2003–08: 42 individuals underwent physician-assisted removal\nOther complaints reported to company included poor fit (n=102), leakage (n=168), messy (n=98)\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nCase report: menstrual cup lodged on cervix, difficult to remove, requiring assistance\nModerate cervical inflammation after retrieval\nDay et al (2012)63\n\n\n\n\nDivacup (vaginal)\nEvent April, 2015: one case report required an emergency room visit for removal\n· ·\nFDA database14\n\n\nReproductive tract observations with use of menstrual cup\nVulva abnormalities\n\n\nSoftcup (cervical)\nBaseline: four (1%) of 393; cycle 1: eight (2%) of 365; cycle 2: six (2%) of 326; cycle 3: five (2%) of 305\nVulva-vaginal inspection at baseline and monthly for 3 months; no p values reported\nNorth et al (2011)13\n\n\nAbnormalities of vaginal wall\n\n\nSoftcup (cervical)\nZero of 44\nVulva-vaginal inspection at baseline and monthly for 3 months\nNorth et al (2011)13\n\n\n\n\nTassette (vaginal)\nZero of 12\nVaginal inspection after 3 months\nPena et al (1962)52\n\n\n\n\nTassette (vaginal)\nZero of 50\nVaginal inspection done; timing of inspections not clear\nKarnaky et al (1962)70\n\n\nAbnormalities of cervix\n\n\nSoftcup (cervical)\nBaseline: 23 (6%) of 390; cycle 1: ten (3%) of 345; cycle 2: six (2%) of 326; cycle 3: four (1%) of 300\nInspection of cervix; no p values reported for differences\nNorth et al (2011)13\n\n\n\n\nSoftcup (cervical)\nAbnormal cervical smear test: baseline: one (<1%) of 406; cycle 1: one (<1%) of 368; cycle 2: two (1%) of 329; cycle 3: zero of 308\nAbnormal cervical smear test results were exclusion criteria at admission, and a reason for discontinuation of the study; no p values reported for differences\nNorth et al (2011)13\n\n\nCondition of vaginal and cervical epithelium\n\n\nSoftcup (cervical)\n44 women examined at baseline, 37 at 2–3 months, and 25 at 5–6 months\n“The Softcup caused no alteration or disruption in vaginal or cervical epithelium, as assessed by colposcopy and cervical cytology”\nNorth et al (2011)13\n\n\nVaginal flora and infections with use of menstrual cup\npH changes of vagina\n\n\nTassette (vaginal)\nZero of 50\nNo abnormalities, vaginal areas where menstrual cup was placed were more acid\nKarnaky et al (1962)70\n\n\n\n\nSoftcup (cervical)\nMean pH at baseline: 4·6 (n=400); cycle 1: 4·6 (n=368); cycle 2: 4·6 (n=329); cycle 3: 4·5 (n=308)\nNo p values reported\nNorth et al (2011)13\n\n\nClue cells (vaginal smear) Lactobaccilus\n\n\nSoftcup (cervical)\nNumber with clue cells: baseline n=6; cycle 1 n=6; cycle 2 n=2; cycle 3 n=4\nSample sizes and p values were not reported\nNorth et al (2011)13\n\n\nLactobaccilus\n\n\nSoftcup (cervical)\n“…before, during, and after use of the cup, vaginal Lactobacillus (normal vaginal flora) was maintained at normal levels.”\nData in figure 3 in publication cannot be extracted; no significant changes according to authors\nNorth et al (2011)13\n\n\nGardnerella vaginalis\n\n\nSoftcup (cervical)\nNo significant changes from baseline-cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nBacterial vaginosis\n\n\nSoftcup (cervical)\nNo significant changes from baseline to cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup 21 (15%) of 144; pads 40 (20%) of 202, and usual practice (control) 32 (21%) of 156; cup vs control p=0·11 and cup vs pads p=0·13; among girls enrolled for ≥9 months: cup 13 (13%) of 101, pads 29 (20%) of 143, usual practice 20 (19%) of 104; cup vs control p=0·07, and cup vs pads p=0·018\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nCandidiasis\n\n\nSoftcup (cervical)\nNumber with candidiasis: baseline n=6; cycle 1 n=6; cycle 2 n=3; cycle 3 n=6\nSample sizes not reported; according to authors, yeast decreased significantly from month 1 to 2\nNorth et al (2011)13\n\n\n\n\nRuby cup (vaginal)\nZero of 18 participants had vaginal candidiasis at follow-up (3–5 months)\nNA\nTellier et al (2012)56\n\n\n\n\nTassette (vaginal)\n\nCandida albicans decreased with the use of the cup\nNR\nKarnaky et al (1962)70\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup 11 (8%) of 143, pads 19 (10%) of 200, usual practice (control) 13 (9%) of 156; cup vs control p=0·87, and cup vs pads p=0·68\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nGroup B Streptococcus\n\n\nSoftcup (cervical)\nNo differences between baseline and cycle 1 to cycle 3\nData in figure 3 in publication cannot be extracted; no significant changes according to authors\nNorth et al (2011)13\n\n\nEnterococcus\n\n\nSoftcup (cervical)\nIncrease in Enterococcus from cycle 2 to cycle 3 (p=0·03)\n“… this increased frequency persisted for 3 months after discontinuing use of the cup, suggesting that factors or behavior other than cup use may have influenced colonization”; data in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nE coli\n\n\nSoftcup (cervical)\nNo significant changes from baseline to cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nEscherichia coli on menstrual cup\n\n\nMooncup (vaginal)\nNine (53%) of 17 if used cup for <6 months; four (22%) of 18 if used for ≥6 months (p=0·12); association between E coli with heavy periods: 61·5% of girls reporting heavy periods had E coli on cups, compared with 22·7% of those stating they did not have heavy periods (p=0·022, no numbers presented)\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nJuma et al (2017)29\n\n\nChlamydia trachomatis\n\n\nMooncup (vaginal)\nStudy end survey: cup three (2%) of 144, pads three (2%) of 201, usual practice (control) seven (5%) of 154; cup vs control p=0·20, and cup vs pads p=0·63\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nTrichomonas vaginalis\n\n\nSoftcup (cervical)\nZero cases at baseline, and cycles 1 to 3\nSample sizes not reported\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup two (1%) of 143, pads five (3%) of 200, usual practice (control) seven (5%) of 154; cup vs control p=0·12, and cup vs pads p=0·36\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\n\n\nRuby cup (vaginal)\nZero of 18 at baseline, and at 3–5 months of follow-up\nNA\nTellier et al (2012)56\n\n\nNeisseria gonorrhoea\n\n\nMooncup (vaginal)\nStudy end survey: cup one (1%) of 144, pads one (1%) of 201, usual practice (control) one (1%) of 154; cup vs control p=0·96, and cup vs pads p=0·81\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\n\n\nRuby cup (vaginal)\nZero of 18 at baseline, and at 3–5 months of follow-up\nNA\nTellier et al (2012)56\n\n\nStaphylococcus aureus\n\n\nSoftcup (cervical)\nNo significant changes in cycles 1–3 compared with baseline\nData in figure 3 of publication cannot be extracted\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nAmong menstrual cup users: four (11%) of 38 in first month of intervention, 13 (9%) of 139 after first month; p=0·83 (median follow-up 4 months, range 2–11 for this substudy); prevalence was 21 (11%) of 197 in sanitary pads group, and 16 (11%) of 153 in usual practice group\nCluster randomised trial in schools; median follow-up 11 months (range 3–15); samples from vaginal swab (self-swabbing)\nJuma et al (2017)29\n\n\n\n\nbe'Cup (vaginal)\nSilicone cup: potentially more S aureus after incubation for 8 h with shaking in a plastic bag with S aureus in one of two cups used, but not when no shaking\nIn-vitro study\nNonfoux et al (2018)73\n\n\n\n\nMe Luna (vaginal)\nThermoplastic isomer cup: no more S aureus after incubation for 8 h with shaking in plastic sac, and not when no shaking\nIn-vitro study\nNonfoux et al (2018)73\n\n\nTSST-1\n\n\nMooncup (vaginal)\n49 schoolgirls with vaginal S aureus had second swab: ten yielded S aureus, two had TSST-1, both in sanitary pad group; the cases were asymptomatic\nCluster randomised trial in schools; median follow-up 11 months (range 3–15); sample from vaginal swab (self-swabbing)\nJuma et al (2017)29\n\n\n\n\nNR\nNo TSST-1 in supernatant of S aureus cultivated for 24 h (incubated aerobically in a still growth environment) in the presence of elastic polymer menstrual cup (n=16 menstrual cups)\nIn-vitro study\nTierno et al (1989)71\n\n\n\n\nTassaway (vaginal)\n\nS aureus MN8 produced no TSST-1 when grown in the presence of Tassaway (elastomeric polymer, n=6), washed or unwashed, no shaking, incubation overnight\nIn-vitro study\nTierno at al (1994)72\n\n\n\n\nbe'Cup (vaginal)\nSilicone cup: potentially more TSST-1 production after incubation for 8 h with shaking in plastic bag with S aureus compared with control, but not when not shaken or with pieces of cup\nIn-vitro study\nNonfoux et al (2018)73\n\n\n\n\nMe Luna (vaginal)\nThermoplastic isomer cup: potentially more TSST-1 production after incubation for 8 h with shaking in plastic bag with S aureus compared with control, but not when not shaken or with pieces of cup\nIn-vitro study\nNonfoux et al (2018)73\n\n\nTSS\n\n\nMooncup (vaginal)\nZero of 192 in trial in Kenya\n“Safety monitoring components comprised routine nurse-based screening, population-based monitoring (school and community) and clinical evaluation of infection with laboratory confirmation”\nJuma et al (2017)29\n\n\n\n\nSoftcup (cervical)\nTwo case reports in the FDA database\nBoth unconfirmed cases of TSS\nNorth et al (2011)13\n\n\n\n\nDivacup (vaginal)\nOne case report: blood cultures and urine culture negative, no culture of the menstrual cup was done\nWoman had history of Hashimoto's thyroiditis and chronic menorrhagia\nMitchell et al (2015)66\n\n\n\n\nMooncup (vaginal)\nEvent February, 2012: TSS 2 days after using of first and new Mooncup resulting in 9 days of inpatient hospital stay; vaginal swab positive for S aureus\n\nHad an IUD, Mooncup was not sent for bacteriological testing\nFDA database14\n\n\n\n\nDivacup (vaginal)\nEvent February, 2015: TSS from Streptococcus resulting in 5 days of i-patient hospital stay; culture of cup isolated group A and B streptococcus\n\nWoman had used Divacup for menstrual period, which started 3 days before illness; menstrual cup was in for 18 h on admission to hospital\nFDA database14\n\n\nUTI\n\n\nRuby cup (vaginal)\nBaseline: four (13%) of 31; at follow-up (after 3–5 months) three (17%) of 18; p=0·65, McNemar test\nOne participant with a UTI at enrolment and follow-up had her cup stolen and used toilet paper in vagina as a tampon\nTellier et al (2012)56\n\n\n\n\nGynaeseal (cervical)\nOne (1%) of 73 had transient dysuria\n“The woman who developed dysuria did not seek treatment and the problem subsided within 24–48 hours”\nCattanach et al (1991)39\n\n\n\n\nSoftcup (cervical)\nUrine analysis done; detailed results not reported\n“Monthly monitoring of gynecological health via urinalysis, pelvic examination with visual evaluation of tissues, vaginal pH, and microscopic wet mount showed no adverse effects of cup use”\nNorth et al (2011)13\n\n\n\n\nSoftcup (cervical)\nEvent August, 2014: UTI confirmed by urine cultures twice after use of softcup\nMedical records were not available for evaluation\nFDA database14\n\n\nInfections overall\n\n\nTassette (vaginal)\n“The amount of bacterial contamination was greatest with the pad, next with the tampon and least with the rubber cup”\nNo data provided; study reported to make cultures from vaginal wall samples and to examine fresh and stained smears for C albicans, Trichomonas vaginalis, Haemophilus vaginalis, and for predominance of Gram-positive or Gram-negative cocci, small rods or long-rod bacilli (Doederlein bacilli)\nKarnaky et al (1962)70\n\n\n\n\nSoftcup (cervical)\nFDA database: one case report\nVaginal infection not further specified; could not be confirmed at follow-up\nNorth et al (2011)13\n\n\n\n\nButterfly cup (vaginal)\n“…none of the women sought treatment for a pelvic infection.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "n (%) or description\nNotes\nData source\n\n\nHandling and positioning of menstrual cup\nVaginal wound\n\n\nCup not clear (Divacup or softcup)\nEvent April, 2012; vaginal wound due to use of menstrual cup, needing treatment from physician for vaginal bleeding\nComplete medical records were not available for evaluation\nFDA database14\n\n\n\n\nSoftcup (cervical)\nReported April, 2012; long-term customer of softcup product claimed vaginal scarring due to use\nMedical director did not find anything in medical records provided by customer related to vaginal health\nFDA database14\n\n\n\n\nSoftcup (cervical)\nFDA database case report: “…cup wore through the vaginal wall, damaging an artery that required surgical repair”\nEvent could not be confirmed; no medical records were available\nNorth et al (2011)13\n\n\nVaginal pain on removal\n\n\nDivacup (vaginal)\nEvent March, 2017; extreme pain on removal (first use), individual stopped using the cup\nSelf-report; no medical report available\nFDA database14\n\n\nPelvic pain\n\n\nSoftcup (cervical)\nEvent February, 2017; pain in lower pelvis and rectum and nausea about 1 h after insertion, no longer present approximately 30 min after removal\nSelf-report; no medical evaluation available; individual stopped use after trying twice (possibly vascular compression)\nFDA database14\n\n\nVaginal irritation\n\n\nGynaeseal (cervical)\nOne (1%) of 73\nSelf-report by participant\nCattanach et al (1991)39\n\n\n\n\nCervix irritation\n\n\n\nMenses cup (vaginal)\nOne (2%) of 51\nCervical smear was normal\nCheng et al (1995)41\n\n\nAllergy and rash\n\n\nNR, vaginal cup\nAllergy: one (1%) of 150; and rash: two (1%) of 150\n· ·\nKakani et al (2017)48\n\n\n\n\nSoftcup (cervical)\nFDA database: two case reports\nNR\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nEvent 2010: silicone allergy in one individual\nSurgery was needed for vaginal repair; manufacturer noted that silicone allergy is very rare\nFDA database14\n\n\nDifficulty with removal requiring professional assistance\n\n\nGynaeseal (cervical)\nOne (5%) of 22\n· ·\nGleeson et al (1993)46\n\n\n\n\nSoftcup (cervical)\nFDA database: three case reports reported by North 2011; one event in 2018\n· ·\nNorth et al (2011),13 FDA database14\n\n\n\n\nSoftcup (cervical)\nReported complaints to company 2003–08: 42 individuals underwent physician-assisted removal\nOther complaints reported to company included poor fit (n=102), leakage (n=168), messy (n=98)\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nCase report: menstrual cup lodged on cervix, difficult to remove, requiring assistance\nModerate cervical inflammation after retrieval\nDay et al (2012)63\n\n\n\n\nDivacup (vaginal)\nEvent April, 2015: one case report required an emergency room visit for removal\n· ·\nFDA database14\n\n\nReproductive tract observations with use of menstrual cup\nVulva abnormalities\n\n\nSoftcup (cervical)\nBaseline: four (1%) of 393; cycle 1: eight (2%) of 365; cycle 2: six (2%) of 326; cycle 3: five (2%) of 305\nVulva-vaginal inspection at baseline and monthly for 3 months; no p values reported\nNorth et al (2011)13\n\n\nAbnormalities of vaginal wall\n\n\nSoftcup (cervical)\nZero of 44\nVulva-vaginal inspection at baseline and monthly for 3 months\nNorth et al (2011)13\n\n\n\n\nTassette (vaginal)\nZero of 12\nVaginal inspection after 3 months\nPena et al (1962)52\n\n\n\n\nTassette (vaginal)\nZero of 50\nVaginal inspection done; timing of inspections not clear\nKarnaky et al (1962)70\n\n\nAbnormalities of cervix\n\n\nSoftcup (cervical)\nBaseline: 23 (6%) of 390; cycle 1: ten (3%) of 345; cycle 2: six (2%) of 326; cycle 3: four (1%) of 300\nInspection of cervix; no p values reported for differences\nNorth et al (2011)13\n\n\n\n\nSoftcup (cervical)\nAbnormal cervical smear test: baseline: one (<1%) of 406; cycle 1: one (<1%) of 368; cycle 2: two (1%) of 329; cycle 3: zero of 308\nAbnormal cervical smear test results were exclusion criteria at admission, and a reason for discontinuation of the study; no p values reported for differences\nNorth et al (2011)13\n\n\nCondition of vaginal and cervical epithelium\n\n\nSoftcup (cervical)\n44 women examined at baseline, 37 at 2–3 months, and 25 at 5–6 months\n“The Softcup caused no alteration or disruption in vaginal or cervical epithelium, as assessed by colposcopy and cervical cytology”\nNorth et al (2011)13\n\n\nVaginal flora and infections with use of menstrual cup\npH changes of vagina\n\n\nTassette (vaginal)\nZero of 50\nNo abnormalities, vaginal areas where menstrual cup was placed were more acid\nKarnaky et al (1962)70\n\n\n\n\nSoftcup (cervical)\nMean pH at baseline: 4·6 (n=400); cycle 1: 4·6 (n=368); cycle 2: 4·6 (n=329); cycle 3: 4·5 (n=308)\nNo p values reported\nNorth et al (2011)13\n\n\nClue cells (vaginal smear) Lactobaccilus\n\n\nSoftcup (cervical)\nNumber with clue cells: baseline n=6; cycle 1 n=6; cycle 2 n=2; cycle 3 n=4\nSample sizes and p values were not reported\nNorth et al (2011)13\n\n\nLactobaccilus\n\n\nSoftcup (cervical)\n“…before, during, and after use of the cup, vaginal Lactobacillus (normal vaginal flora) was maintained at normal levels.”\nData in figure 3 in publication cannot be extracted; no significant changes according to authors\nNorth et al (2011)13\n\n\nGardnerella vaginalis\n\n\nSoftcup (cervical)\nNo significant changes from baseline-cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nBacterial vaginosis\n\n\nSoftcup (cervical)\nNo significant changes from baseline to cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup 21 (15%) of 144; pads 40 (20%) of 202, and usual practice (control) 32 (21%) of 156; cup vs control p=0·11 and cup vs pads p=0·13; among girls enrolled for ≥9 months: cup 13 (13%) of 101, pads 29 (20%) of 143, usual practice 20 (19%) of 104; cup vs control p=0·07, and cup vs pads p=0·018\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nCandidiasis\n\n\nSoftcup (cervical)\nNumber with candidiasis: baseline n=6; cycle 1 n=6; cycle 2 n=3; cycle 3 n=6\nSample sizes not reported; according to authors, yeast decreased significantly from month 1 to 2\nNorth et al (2011)13\n\n\n\n\nRuby cup (vaginal)\nZero of 18 participants had vaginal candidiasis at follow-up (3–5 months)\nNA\nTellier et al (2012)56\n\n\n\n\nTassette (vaginal)\n\nCandida albicans decreased with the use of the cup\nNR\nKarnaky et al (1962)70\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup 11 (8%) of 143, pads 19 (10%) of 200, usual practice (control) 13 (9%) of 156; cup vs control p=0·87, and cup vs pads p=0·68\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nGroup B Streptococcus\n\n\nSoftcup (cervical)\nNo differences between baseline and cycle 1 to cycle 3\nData in figure 3 in publication cannot be extracted; no significant changes according to authors\nNorth et al (2011)13\n\n\nEnterococcus\n\n\nSoftcup (cervical)\nIncrease in Enterococcus from cycle 2 to cycle 3 (p=0·03)\n“… this increased frequency persisted for 3 months after discontinuing use of the cup, suggesting that factors or behavior other than cup use may have influenced colonization”; data in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nE coli\n\n\nSoftcup (cervical)\nNo significant changes from baseline to cycle 3 according to authors\nData in figure 3 in publication cannot be extracted\nNorth et al (2011)13\n\n\nEscherichia coli on menstrual cup\n\n\nMooncup (vaginal)\nNine (53%) of 17 if used cup for <6 months; four (22%) of 18 if used for ≥6 months (p=0·12); association between E coli with heavy periods: 61·5% of girls reporting heavy periods had E coli on cups, compared with 22·7% of those stating they did not have heavy periods (p=0·022, no numbers presented)\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nJuma et al (2017)29\n\n\nChlamydia trachomatis\n\n\nMooncup (vaginal)\nStudy end survey: cup three (2%) of 144, pads three (2%) of 201, usual practice (control) seven (5%) of 154; cup vs control p=0·20, and cup vs pads p=0·63\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\nTrichomonas vaginalis\n\n\nSoftcup (cervical)\nZero cases at baseline, and cycles 1 to 3\nSample sizes not reported\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nStudy end survey: cup two (1%) of 143, pads five (3%) of 200, usual practice (control) seven (5%) of 154; cup vs control p=0·12, and cup vs pads p=0·36\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\n\n\nRuby cup (vaginal)\nZero of 18 at baseline, and at 3–5 months of follow-up\nNA\nTellier et al (2012)56\n\n\nNeisseria gonorrhoea\n\n\nMooncup (vaginal)\nStudy end survey: cup one (1%) of 144, pads one (1%) of 201, usual practice (control) one (1%) of 154; cup vs control p=0·96, and cup vs pads p=0·81\nCluster randomised trial of schools; median follow-up 11 months (range 3–15)\nPhillips-Howard et al (2016)5\n\n\n\n\nRuby cup (vaginal)\nZero of 18 at baseline, and at 3–5 months of follow-up\nNA\nTellier et al (2012)56\n\n\nStaphylococcus aureus\n\n\nSoftcup (cervical)\nNo significant changes in cycles 1–3 compared with baseline\nData in figure 3 of publication cannot be extracted\nNorth et al (2011)13\n\n\n\n\nMooncup (vaginal)\nAmong menstrual cup users: four (11%) of 38 in first month of intervention, 13 (9%) of 139 after first month; p=0·83 (median follow-up 4 months, range 2–11 for this substudy); prevalence was 21 (11%) of 197 in sanitary pads group, and 16 (11%) of 153 in usual practice group\nCluster randomised trial in schools; median follow-up 11 months (range 3–15); samples from vaginal swab (self-swabbing)\nJuma et al (2017)29\n\n\n\n\nbe'Cup (vaginal)\nSilicone cup: potentially more S aureus after incubation for 8 h with shaking in a plastic bag with S aureus in one of two cups used, but not when no shaking\nIn-vitro study\nNonfoux et al (2018)73\n\n\n\n\nMe Luna (vaginal)\nThermoplastic isomer cup: no more S aureus after incubation for 8 h with shaking in plastic sac, and not when no shaking\nIn-vitro study\nNonfoux et al (2018)73\n\n\nTSST-1\n\n\nMooncup (vaginal)\n49 schoolgirls with vaginal S aureus had second swab: ten yielded S aureus, two had TSST-1, both in sanitary pad group; the cases were asymptomatic\nCluster randomised trial in schools; median follow-up 11 months (range 3–15); sample from vaginal swab (self-swabbing)\nJuma et al (2017)29\n\n\n\n\nNR\nNo TSST-1 in supernatant of S aureus cultivated for 24 h (incubated aerobically in a still growth environment) in the presence of elastic polymer menstrual cup (n=16 menstrual cups)\nIn-vitro study\nTierno et al (1989)71\n\n\n\n\nTassaway (vaginal)\n\nS aureus MN8 produced no TSST-1 when grown in the presence of Tassaway (elastomeric polymer, n=6), washed or unwashed, no shaking, incubation overnight\nIn-vitro study\nTierno at al (1994)72\n\n\n\n\nbe'Cup (vaginal)\nSilicone cup: potentially more TSST-1 production after incubation for 8 h with shaking in plastic bag with S aureus compared with control, but not when not shaken or with pieces of cup\nIn-vitro study\nNonfoux et al (2018)73\n\n\n\n\nMe Luna (vaginal)\nThermoplastic isomer cup: potentially more TSST-1 production after incubation for 8 h with shaking in plastic bag with S aureus compared with control, but not when not shaken or with pieces of cup\nIn-vitro study\nNonfoux et al (2018)73\n\n\nTSS\n\n\nMooncup (vaginal)\nZero of 192 in trial in Kenya\n“Safety monitoring components comprised routine nurse-based screening, population-based monitoring (school and community) and clinical evaluation of infection with laboratory confirmation”\nJuma et al (2017)29\n\n\n\n\nSoftcup (cervical)\nTwo case reports in the FDA database\nBoth unconfirmed cases of TSS\nNorth et al (2011)13\n\n\n\n\nDivacup (vaginal)\nOne case report: blood cultures and urine culture negative, no culture of the menstrual cup was done\nWoman had history of Hashimoto's thyroiditis and chronic menorrhagia\nMitchell et al (2015)66\n\n\n\n\nMooncup (vaginal)\nEvent February, 2012: TSS 2 days after using of first and new Mooncup resulting in 9 days of inpatient hospital stay; vaginal swab positive for S aureus\n\nHad an IUD, Mooncup was not sent for bacteriological testing\nFDA database14\n\n\n\n\nDivacup (vaginal)\nEvent February, 2015: TSS from Streptococcus resulting in 5 days of i-patient hospital stay; culture of cup isolated group A and B streptococcus\n\nWoman had used Divacup for menstrual period, which started 3 days before illness; menstrual cup was in for 18 h on admission to hospital\nFDA database14\n\n\nUTI\n\n\nRuby cup (vaginal)\nBaseline: four (13%) of 31; at follow-up (after 3–5 months) three (17%) of 18; p=0·65, McNemar test\nOne participant with a UTI at enrolment and follow-up had her cup stolen and used toilet paper in vagina as a tampon\nTellier et al (2012)56\n\n\n\n\nGynaeseal (cervical)\nOne (1%) of 73 had transient dysuria\n“The woman who developed dysuria did not seek treatment and the problem subsided within 24–48 hours”\nCattanach et al (1991)39\n\n\n\n\nSoftcup (cervical)\nUrine analysis done; detailed results not reported\n“Monthly monitoring of gynecological health via urinalysis, pelvic examination with visual evaluation of tissues, vaginal pH, and microscopic wet mount showed no adverse effects of cup use”\nNorth et al (2011)13\n\n\n\n\nSoftcup (cervical)\nEvent August, 2014: UTI confirmed by urine cultures twice after use of softcup\nMedical records were not available for evaluation\nFDA database14\n\n\nInfections overall\n\n\nTassette (vaginal)\n“The amount of bacterial contamination was greatest with the pad, next with the tampon and least with the rubber cup”\nNo data provided; study reported to make cultures from vaginal wall samples and to examine fresh and stained smears for C albicans, Trichomonas vaginalis, Haemophilus vaginalis, and for predominance of Gram-positive or Gram-negative cocci, small rods or long-rod bacilli (Doederlein bacilli)\nKarnaky et al (1962)70\n\n\n\n\nSoftcup (cervical)\nFDA database: one case report\nVaginal infection not further specified; could not be confirmed at follow-up\nNorth et al (2011)13\n\n\n\n\nButterfly cup (vaginal)\n“…none of the women sought treatment for a pelvic infection.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In India22 and Tanzania,43 the uptake of menstrual cups was significantly slower than uptake of pads (appendix p 24).22, 43 In 15 studies with relevant information, 73% (pooled estimate: n=1144, 95% CI 59–84; I2=96%) of participants reported willingness to continue use of the menstrual cup after the study (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  }
]